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ABSTRACT 
 
Folic acid (FA) is an amino acid that helps in the replication of normal cells and it deficiency 
may lead to oncogenic cells development. Methotrexate (MTX) on the other hand is a highly 
potent drug against leukemia and other neoplasias, which can induce toxic side effects and 
drug resistance to target cells. The principal objective was to develop a bioconjugate that will 
enhance therapeutic effectiveness of these agents (FA and MTX) using functionalized carbon 
nanotubes and polymer toward cancer cells. Furthermore, bioreversible binding to a water-
soluble and biocompatible carrier polymer and carbon nanotubes are advanced technology 
designed to circumvent critical pharmacological and efficacious biological action. 
 
The formation of biofissionable bond (CONH) for drug release was evaluated in this work by 
using nuclear magnetic resonance (NMR) spectra with D2O as solvent, and infrared (IR) 
spectra to identify the necessary peak shifts for the bioreversible conjugation of FA and MTX 
as anticancer drug. Polyaspartamide and carbon nanotubes (CNTs) were both functionalized 
and used as carriers for solubility behavior, steric accessibility and reactivity of anchoring sites, 
aiming to enhance therapeutic effectiveness of MTX.                                                                                         
 
In order to obtain the polymeric carrier, to polysuccinimide (PSI) synthesized via 
polycondensation of aspartic acid was attached 3-(N,N–dimethylamino)propylamine (DMP) 
and 1,3-propylenediamine (PDA) for solubility behavior and reactivity of anchoring of the 
drug respectively. This, through the use of an ester 2-(1H-benzotrial-1-yl)-1,1,3,3-
tetramethylurium hexafluorophosphate (HBTU), as coupling agent led to the polymer drug 
conjugate after reacting with FA. The reaction was subjected to the polymer cleavage which 
caused the dropping of yield after chromatography and dialysis operations. After kinetic 
reaction investigation, the optimum reaction time was set within the range of 120-130 minutes 
for an optimum yield of coupling within the range of 80-85% where the incorporation of FA in 
the polymer was maximum though the polymer cleavage. In addition, CNTs obtained via 
chemical vapour deposition (VCD) was covalently functionalized at RT, 50ºC and 100ºC with 
a mixture of sulphuric and nitric acids to generate the phenol and carboxyl groups on the 
surface, and at 230 ºC with aspartic acid to generate only the carboxyl group. It resulted that 
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the mol ratio (OH/COOH) was increasing, the size of f-CNTs was decreasing from 80, 30 to 
20nm and the water solubility was increasing with the increase in temperature from RT, 50ºC 
to 100ºC. The carboxyl on the surface of f-CNTs was attached to DMP and FA through HBTU 
to get f-CNTs-FA conjugate. This resulted to the prodrug with different sizes of 50nm and 
170nm with 94% and 101.3% incorporation of folic acid respectively. 
 
CNTs noncovalently coated with polysuccinimide (PSI) in DMF at 160ºC were attached to 
DMP and PDA. Thereafter, FA reacted with PDA via HBTU to give a prodrug of 60nm with 
105.3% FA incorporation. The f-CNTs functionalized with polymer can be more beneficial due 
to the size for the cell penetration and average molecular weight for renal clearance. Therefore 
the biomedical evaluation is recommended for future work.   
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background and Motivation 
 
1.1.1 Folic acid 
 
                   Folic acid is needed for the de novo synthesis of the nucleoside thymidine required for 
DNA synthesis. The presence of folic acid causes the synthesis of DNA, RNA, 
thymidylates, and proteins by the affinity that it can develop with dihydrofolate reductase 
(DHFR), an enzyme that is part of the folate synthesis metabolic pathway. Dihydrofolate 
reductase catalyses the conversion of dihydrofolate to the active tetrahydrofolate. Folic 
acid is an important nutrient for the growth of cells via essentially purine and pyrimide 
synthesis. Adequate folate intake helps the replication of normal cells conducing to good 
health. Thereto adequate folate intake, causing rapid cell division and growth, is helpful 
for the pregnancy and the infancy.(1) Thus, the first four weeks of pregnancy (when most 
women do not even realize they are pregnant) require folic acid for proper development 
of the brain, skull, and spiral cord. While folate deficiency, affecting hematopoietic cells 
and neoplasms, hinders DNA synthesis and cell division. RNA transcription and 
subsequent protein synthesis are less affected by folate deficiency, as the mRNA can be 
recycled and used again (as opposed to DNA synthesis where a new genomic copy must 
be created). Both adults and children need folate to form normal red and white blood cells 
and prevent anemia (2), because some of those large cells, although immature 
(reticulocytes) are released early from the marrow in an attempt to compensate for the 
anemia (3).  
                    
In the event of random proliferation of cells, condition becomes harmful to the abnormal 
cells; enhanced chemotherapy will be requested to stop the cause of the growth of cells. 
The association between folate and cancer appears to be complex. It has been suggested 
that folate may help prevent cancer, as it is involved in the synthesis, repair, and 
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functioning of DNA, and a deficiency of folate may result in damage to DNA that may 
lead to cancer (4). 
 
1.1.2 Methotrexate (MTX)  
 
Methotrexate was originally used as part of combination chemotherapy regimens to treat 
many kinds of cancers. It is still the mainstay for treatment of many neoplastic disorders 
including acute lymphoblastic leukemia. The metabolism of 7,8-dihydrofolate to 5,6,7,8 
tetrahydrofolate smashes rapidly into DNA synthesis which generates the multiplication 
of cells in disorder, results to cancer. The activity of this metabolism is accelerated with 
the presence of dihydrofolate reductase, an enzyme that is part of the folate synthesis 
metabolic pathway.      
 
MTX competitively and reversibly inhibits dihydrofolate reductase (DHFR) due to its 
affinity for DHFR which is about one thousand-fold that of folate for DHFR. As a result, 
there is a reduction in purine and pyrimidine-nucleic acid metabolism. MTX acts 
especially during DNA and RNA synthesis, and thus it is cytotoxic during the S-phase of 
cell cycle. Note that MTX has a greater toxic effect on rapidly dividing cells, which 
replicate their DNA more frequently and thus inhibits the growth and proliferation of 
these non-cancerous cells, as well as side effects.  MTX is absorbed completely from the 
intestine, and metabolized via the kidney. It enters the cell and is polyglutamated like 
folic acid, therefore retaining within the cell and providing its effectiveness. 
 
MTX tends to work faster and more effectively compared to most disease modifying 
antirheumatic drug. It has a considerable interaction with many drugs. Caution should be 
applied when used together with trimethoprim, probenecid, and nonsteroidal anti-
inflammatory drugs, especially in the face of renal impairment. Lower doses of MTX 
have been shown to be very effective for the management of rheumatoid arthritis and 
psoriasis. In these cases, inhibition of dihydrofolate reductase (DHFR) is not thought to 
be the main mechanism, rather the inhibition of enzymes involved in purine metabolism, 
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leading to accumulation of adenosine, or the inhibition of T cell activation and 
suppression of intercellular adhesion molecule expression by T cells (5).  
 
1.1.3. Polymer-drug conjugation 
 
Chemotherapy is a significant module among many emerging biomedical technologies 
used for cancer management and control. Among the requirements that must be fulfilled 
by the systemically acting antiproliferative medicinal agent in order to qualify as an 
efficacious carcinostatic drug, the following may be cited: (1) Complete solubility in 
aqueous media, ensuring rapid dissolution and dissipation in the (aqueous) vascular 
system. (2) Low systemic toxicity, allowing for continuing drug administration at high 
dose levels with resultant large therapeutic index. (3) Non-polar, uncharged structure, a 
precondition for efficacious membrane crossing and cell entry by the normal passive 
diffusion mechanism, with optimal intracellular bioavailability and minimal risk of 
capture in the interstitial fluid by the reticuloendothelial system. (4) Cell-specific drug 
action, leading to preferential accumulation in the cancerous tissue while leaving healthy 
tissue unaffected. This presupposes that a specific drug, or drug combination, must be 
available for each one of the different kinds of proliferative syndromes defined as 
cancers. (5) Extended circulation half-life, concomitant with grossly retarded elimination 
through catabolic processes, serum protein binding, or macrophage action. (6) 
Continuous long-term effectiveness with low probability of emerging drug resistance, 
thus permitting ongoing treatment at sustained dose level. 
 
With the realization of pathological complexity of cancerous growths and the multitude 
of hurdles a therapeutic agent has to overcome in order to act incisively on site, to 
eradicate a neoplastic lesion, it has become clear that, at the current level of proficiency, 
long-lasting remissions can be achieved by chemotherapeutic means only for a very 
selected number of cancers. More often, remissions are temporary, requiring additional 
treatment modes. Success rates for modalities combating invasive growth are extremely 
low, and therapies increasingly lack effectiveness upon prolonged systemic drug 
administration. The reasons are obvious: most of the anticancer drugs in current clinical 
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administration lack the qualifying features listed in the foregoing, to a major or lesser 
extent. Specifically, the drugs generally reach unduly low levels of bioavailability as they 
possess polar or salt-like structures, lack cell specificity, or are rapidly eliminated from 
central circulation by a variety of depletion mechanisms. More crucially, they generally 
cause severe toxic side-effects in addition to showing a tendency to elicit single, or even 
multiple, drug resistance in the affected cells. As a consequence, the therapeutic 
effectiveness of present-generation anticancer agents has remained unsatisfactorily low, 
in spite of extensive research worldwide. A state of the art treatment of the topic is found 
in a reference book published by the American Chemical Society (6). 
 
With recognition given to the therapeutic inadequacies associated with most currently 
administered antitumor drugs, a special trend in drug research has been observed in 
recent years which aims at the provision of pharmacokinetic assistance to a given drug 
system through attachment to macromolecular compounds, acting as protecting transport 
vehicles and drug delivery agents. This trend has resulted in the development of drug-
containing liposomes, microencapsulations, and nanoparticles as variably successful 
delivery systems. One of the most promising macromolecular drug release strategies 
utilizes water-soluble, biodegradable polymers as carriers of the medical agents. This 
strategy has in recent years matured into a highly successful tool of chemotherapy, 
circumventing many of the problems associated with the direct administration of the 
original low-molecular-mass drugs. The polymer-drug conjugation concept, pioneered by 
Chu and Whiteley (7) and significantly refined by Rigsdorf (8), is based on a carrier model 
comprising a linear polymer chain composed of subunits bearing water-solubilizing 
groups, other subunits equipped with functional groups suitable for reversible drug 
binding (anchoring). Other subunits comprise a homing device, i.e. some molecular entity 
capable of directing the conjugate molecular selectively to the target tissue. The 
conjugate nearly always represents a prodrug from which the active agent is released in 
the predestined biological environment (generally the cytoplasmic lysosomes) by 
hydrolysis or through enzymatic action.  
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Several excellent reviews are available in which the fundamental structural requirements 
and performance criteria are discussed in detail (9, 10). The most outstanding benefits to 
derive from drug conjugation include the following:  
(i) Even if inherently hydrophobic and insoluble in water, the drug will be carried 
immediately into the aqueous phase of the central circulation system or the 
intraperitonal cavity. This will ensure rapid drug distribution in the fluid 
system. 
(ii) While in transit in the central circulation system, the polymer-bound drug will 
experience temporary protection from enzymatic attack, serum protein 
binding and other scavenging processes. This will lead to reduced renal 
clearance and prolonged serum life-time with substantially enhanced drug 
bioavailability. 
(iii) The polymer-drug conjugate will experience facilitated endocytotic cell entrance, 
thus circumventing potential problems caused by drug polarity or iconicity in 
the normal process of membrane crossing, by passive diffusion common to 
nonpolymeric solutes. The mechanism is pinocytotic in nature and thus not 
subject to the limitations imposed by the reticulo-endothelical system on 
phagocytotically captured particles. Ideally, adsorptive pinocytosis is utilized 
by the conjugate for increased efficiency of translocation, and cationic 
polymers are good examples of compounds so translocated. Endocytotic cell 
entrance may additionally assume unique importance where drug resistance, 
due to excessive P-glycoprotein-medicated efflux from the cytoplasm has 
become an issue.  
(iv) Enhanced drug affinity for the transformed (i.e. cancerous) cell may be achieved 
by incorporation of a homing group, e.g. certain sugars or strongly cationic 
functionalities, as well as, in the ultimately perfect form, monoclonal 
antibodies. 
(v) Drastically reduced toxic side effects will result from the “anchored” nature of the 
drug in the initial stage of administration, restricting it to the desired 
pharmacokinetic path and reducing the risk of accumulation in healthy tissue. 
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(vi) Polymer conjugates, in common with macromolecules in general, tend to 
accumulate in solid tumors because of enhanced intratumoral vascular 
permeability, allowing for substantial leakage of the polymeric molecules into 
the tumor tissue. Whereas, in normal tissues, macromolecules in intestinal 
space are efficiently recovered by the lymphatic system, this lymphatic 
clearance is grossly retarded in tumor tissue. And this represents a weighty 
factor contributing to the tumoritropic characteristics of polymers. This 
enhanced permeability and retention (EPR) effect associated with 
macromolecules, renders drug administration more efficacious while reducing 
systemic toxicity in other organs; see (v), above. 
 
The water-soluble, intravenously administered conjugate will be constructed so as to: (i) 
rapidly enter and dissipate in the aqueous central circulation; while in transit, the drug 
will be protected against premature renal clearance (thus reducing nephrotoxicity), serum 
protein binding and capture by the reticuloendothelial system (thus avoiding irreversible 
inactivation); (ii) remain polymer-bond while in circulation (thus preventing drug serum 
levels from exceeding the toxic level); (iii) undergo facilitated (pinocytic) entry into the 
cancerous target cell (thus overcoming problems of charge, polarity, or excessive drug 
efflux, the last-named factor being a cause of drug resistance); and (vi) accumulate 
preferentially in tumor tissue because of vascular leakage and reduced lymphatic 
clearance. The cited factor will combine to achieve a reduction of toxicity and more 
effective drug utilization. For proper functioning in the biological environment, in 
accordance with this proposal, the carrier polymers will be designed so as to (i) provide 
and retain water solubility of the derived conjugate, (ii) feature biocompatibility and 
biodegradability, (iii) provide preferential attraction to the cancerous cell, and              
(iv) possess drug-binding functionality capable of drug release in the cytoplasmic 
environment. With the conjugation to a carrier polymer so characterized, the drug 
systems, even if inherently hydrophobic and insoluble in water, will smoothly and rapidly 
enter (and be distributed in) the aqueous fluid system and, while in transit, will benefit 
from temporary protection against catabolic elimination. In addition, they are expected to 
experience facilitated transcytotic epithelial barrier crossing and pinocytotic target cell 
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entry, thus overcoming problems in membrane penetration and risk of drug rejection by 
target tissues, having acquired drug resistance. 
 
1.1.4. Drug delivery with carbon nanotubes 
 
The search for new and effective drug delivery systems is a fundamental issue of 
continuous interest (11). A drug delivery system is generally designed to improve the 
pharmacological and therapeutic profile of drug molecule (12). A wide variety of delivery 
systems are currently available (13). The ability of functionalized carbon nanotube (f-
CNT) to penetrate into the cells, offers the potential of using f-CNT as vehicles for the 
delivery of small drug molecules (14, 15). However, the use of f-CNT for the delivery 
systems of small drug molecules able to carry one or more therapeutic agents with 
recognition capacity, optical signal of imaging and/or specific targeting, is of 
fundamental advantage, for example in the treatment of cancer and different types of 
infectious diseases (16). For this purpose a new strategy for the multiple functionalization 
of CNT with different types of molecules (17) has been developed. A florescent probe for 
tracking the cellular uptake of the material and an antibiotic moiety as the active 
molecule were covalently linked to CNT where multi wall carbon nanotubes (MWNT) 
were functionalized with amphotericin B and fluorescein. 
The antibiotics linked to nanotubes was easily internalized into mammalian cells without 
toxic effects in comparison with the antibiotic incubated alone. In addition, amphotericin 
B bound to CNT preserved its high antifungal activity against a broad range of 
pathogens, including Candida albicans, Cryptococcus neoformans and Candida 
parapsilosi.  
 
In view of these results, f-CNTs represent a new, emerging class of delivery systems for 
the transport and translocation of drug molecules into different types of mammalian cells. 
Although these CNT conjugates displayed no cytotoxicity in vitro, further development 
will be important to assess their metabolism, biodistribution and clearance from body. 
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1.2. Problem statement  
 
Cancer presents one of the most formidable health problems worldwide. More than 10 
million people are diagnosed with cancer every year. The world health organization 
(WHO) estimated that there will be 12 million new cases every year by 2030. Cancerous 
diseases cause 6 million deaths every year, almost 12% of worldwide mortality. The 
incidence and mortality rates of certain types of cancer have wide geographical 
differences, which are attributed to racial, cultural, and especially environmental 
influences (18). 
 
In South Africa, cancer is the second most common cause of death in the white, coloured, 
and Asian population, and the third most common cause in the black population group(19). 
On average, South Africa rates for certain malignancies such as cervical, oesophageal, 
and skin cancers rank among the highest world-wide. Cancers of the lung and prostate 
rate among the top six cancers with white and non-white, and melanoma represents one 
of top six cancers with white females. Other types of cancer, including the various forms 
of leukemia, although of lower incidence, are nonetheless a cause for serious concern. 
 
The problem will be aggravated in the years to come as increasing urbanization is 
expected to create environmental and dietary conditions conducive to further initiation 
and spread of cancers.  It will be further compounded by finding that cancerous 
afflictions occur in approximately one-third of all male and female adult breadwinners in 
the age bracket of 15-54 years. A novel factor now coming into play is the rapid spread of 
AIDS; immunodepressed patients will be at special risk to develop early cancerous 
lesions, and virus-related cancers may well find particularly suitable targets among such 
patients (20).  
 
The available anticancer drugs have distinct mechanisms of action, which may vary in 
their effects on different types of normal and cancer cells. Chemotherapy constitutes an 
important cancers treatment modality, alone or in conjunction with other treatment 
regimens. However, despite much progress in drug research, complete cures by 
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chemotherapy are still the exception rather than the rule. In general, remissions remain 
incomplete or short-lived, especially whenever secondary cancers (metastases) have 
developed or resistance phenomena emerged. The inadequate effectiveness of present-
day anticancer drugs can be traced to a combination of factors, including poor solubility 
in aqueous media, inefficacious membrane crossing and cell entry because of structural 
charge or polarity, lack of cell specificity, short serum half-life, and most critically, 
excessive toxicity and a propensity for induction of drug resistance. For this reason, 
cancer chemotherapy may consist of using several drugs in combination for varying 
lengths of time.  
 
1.3. Research questions 
 
There are many modalities for cancer treatment. They are highly variable and dependent 
on a number of factors such as the type, location and amount of disease and the health 
status of the patient. The treatments are designed to directly kill or remove the cancer 
cells or to lead to their eventual death by depriving them of signals needed for cell 
division, or to stimulate the host immune system after killing or removal of these cells. 
The four principal modalities utilized are surgery, radiation, chemotherapy, and 
immunotherapy. Many questions have been asked on chemotherapy, which is the impetus 
of this study and will create awareness of some new therapies still in their infancy. 
Chemotherapy, while representing a vital component of cancer treatment modalities, has 
not yet fulfilled basic expectations. Cure rates are unsatisfactory and relapses frequent for 
reasons of limited therapeutic drug efficacy, detrimental side effects, resistance problems 
and pharmacological deficiencies.    
 
1.4.     Research hypothesis 
 
Within the framework of macromolecular and carbon nanotubes drug research in the 
Schools of Chemistry and Chemical Engineering of the  University of the Witwatersrand, 
the present project represents a contribution to cancer drug development.  
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It is the project’s primary objective, addressing the problem of inefficiency of drug, to 
provide a vehicle for improved pharmacokinetic utilization of anticancer agents. Various 
strategies will be used to set the active drug out of the critical pharmacological obstacles 
which render the clinical usefulness very inadequate. Among various strategies, the 
formation of bioreversible bond between a medicinal drug and water-soluble and 
biocompatible carriers (polymers and carbon nanotubes) represents an advanced 
technology that is designed to avoid the critical pharmacological obstacles which the drug 
must clear for efficacious biological action. The polymer-drug conjugate and carbon 
nanotubes-drug conjugate resulting from the carrier-drug anchoring step, act as free-form 
at the target site.  
 
This will be accomplished through bioreversible conjugation of selected anticancer drug 
models with water-soluble macromolecular and functionalized carbon nanotube carriers, 
designed in accordance with specific biomedical requirements. Especially carbon 
nanotubes will be used as platforms for multiple derivatization by loading their surface 
with therapeutic agents (treatment), aiming to be rendered fluorescent, magnetic, or 
radionuclide probe (tracking), and active recognition segments (targeting). The 
conjugates will be constructed so as to act as prodrugs, comprising the chosen drug 
systems: folic acid and methotrexate (hereinafter abbreviated to MTX). Following 
facilitated pharmacokinetic pathways, the bioactive drug species will be released in the 
transformed target cell by hydrolytic or enzymatic mechanisms. 
 
In the polymer Laboratory of school of chemistry in the University of Witwatersrand, the 
concept of polymer-drug conjugation has been utilized in numerous projects aiming at 
increasing the therapeutic effectiveness of experimental anticancer-active agents, and 
preliminary biomedical screening results reflect high to excellent activity of the 
conjugates tested. The experience gained in these preceding projects is being used to 
propel this project forward.  
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1.5.     Research objectives 
 
The principal objective is to develop a class of anticancer agents with enhanced 
therapeutic effectiveness. The proposed approach will be instrumental in fulfilling the 
project’s specific aims, viz. (1) reduction of toxic side effects and emerging resistance 
problems; (2) widening of the agents’ activity spectrum and therapeutic window; (3) 
increase in bioavailability through enhanced water solubility, serum residence time, 
accumulation in the tumor tissue, and pinocytotic cell entry; and, most importantly; (4) 
development of combination drug conjugates for ultimate co-administration with 
mainstream drug conjugates of MTX and folic acid.  
 
1.6.     Expected Contribution to Knowledge  
 
1. In this project, a series of the novel drug systems with high carcinostatic activity 
will be synthetically and analytically developed as contribution to the national and 
worldwide cancer management programs. 
2. This work will provide adequate information on the development of good vehicle 
for improved pharmacokinetic utilization of anticancer agents. 
3. This work will provide useful information from biomedical testing results. In vitro 
screening tests will be performed in order to allow the synthesis work to be 
redirected as required for the attainment of optimal biological activity. 
4. Using two different methods, the first is the conjugation of selected anticancer 
drug models with water-soluble macromolecular carriers; and the second is the 
functionalized carbon nanotubes. This work will assist in finding the best 
performing method. 
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1.7.     Terminology and definition 
 
1.7.1. Deoxyribonucleic acid (DNA) 
 
DNA is a nuclei acid that contains the genetic instructions used in the development and 
functioning of all known living organisms. The main role of DNA molecules is the long-
term storage of information and DNA is often compared to a set of blueprints, since it 
contains the instructions needed to construct other components of cells, such as proteins 
and RNA molecules. The DNA segments that carry this genetic information are called 
genes, but other DNA sequences have structural purposes, or are involved in regulating 
the use of this genetic information. 
 
Chemically, DNA is a long polymer of simple units called nucleotides, with a backbone 
made of sugars and phosphate groups joined by ester bond. Attached to each sugar is one 
of four types of molecules called bases. It is the sequence of these four bases along the 
backbone that encodes information. This information is read using the genetic code, 
which specifies the sequence of the amino acids within proteins. The code is read by 
copying stretches of DNA into the related nucleic acid RNA, in a process called 
transcription. Most of these RNA molecules are used to synthesize proteins, but others 
are used directly in structures such as ribosomes and spliceosomes.  
Within cells, DNA is organized into structures called chromosomes and the set of 
chromosomes within a cell make up a genome. These chromosomes are duplicated before 
cells divide, in a process called DNA replication. Eukaryotic organisms such as animals, 
plants, and fungi store their DNA inside the cell nucleus, while in prokaryotes such as 
bacteria it is found in the cell’s cytoplasm. Within the chromosomes, chromatin proteins 
such as histones compact and organize DNA, which helps control its interactions with 
other proteins and thereby control which genes are transcribed. 
 
Ribonucleic acid or RNA as a nucleic acid polymer consisting of nucleotide monomers, 
plays several important roles in the processes that translate genetic information from 
DNA into protein product. Thus, RNA acts as a messenger between DNA and the protein 
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synthesis complexes known as ribosomes, forms vital portions of ribosomes, and acts as 
an essential carrier molecule for amino acids to be used in protein synthesis. 
 
1.7.2. Enzymes 
 
Enzymes are proteins that catalyze (i.e. accelerate) chemical reaction (21).In enzymatic 
reactions, the molecules at the beginning of the process are called substrates, and the 
enzyme converts them into different molecules, the products. Almost all processes in a 
biological cell need enzymes in order to occur at significant rates. Since enzymes are 
extremely selective for their substrates and speed up only a few reactions from among 
many possibilities, the set of enzymes made in a cell determines which metabolic 
pathways occur in that cell. 
 
Enzyme activity can be affected by other molecules. Inhibitors are molecules that 
decrease enzyme activity; activators are molecules that increase activity. Many drugs and 
poisons are enzyme inhibitors. Activity is also affected by temperature, chemical 
environment (e.g. pH), and the concentration of substrate. Some enzymes are used 
commercially, for example, in the synthesis of antibiotics. In addition, some household 
products use enzymes to speed up biomedical reactions (e.g. enzymes in biological 
washing powders break down protein or fat stains on clothes; enzymes in meat 
tenderizers break down proteins, making the meat easier to chew) (22).  
 
1.7.3. Chemotherapy 
 
Chemotherapy is given to eradicate and stop the progress of the expansion of secondary 
tumors resulting from outstanding and untraceable cancer cells that often reside in the 
body after surgery.  
 
During chemotherapy many anticancer agents and other chemical entities aim to apply 
immune-stimulating effects on the cancer patient’s immune system. Chemical agents 
impressing toxic effects on the cancerous cell, for the most part cause interference with 
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the cell’s replicative mechanism and therefore with intracellular nucleic acid synthesis 
and the ultimate role played by the nuclear DNA in mitosis. Whenever the target tissue 
consists of rapidly dividing cells, as is generally the case in a malignant system, the 
effectiveness of the anticancer drugs is generally, although not exclusively, at an optimal 
level. Nevertheless, the human body disposes a number of compartments in which 
normal, i.e. healthy cells are required to replicate at a high rate for the accomplishment of 
their physiological role, e.g. the bone marrow, the linings of the gut and the urinary tract. 
It is, indeed, in these compartments where most of the systemically acting anticancer 
drugs exert their most undesirable toxic side effects, as the rapidly proliferating cells do 
not provide sufficiently long-time intervals during which normal repair mechanism, 
mediated by selective repair enzymes, can remain operative (23, 24).   
 
1.7.4. Antimetabolites  
 
The antimetabolites, as structural analogs of naturally occurring compounds, interfere 
with the production of nucleic acids and work through a variety of mechanisms, including 
competition for binding sites on enzymes and incorporation into nucleic acids. 
Antimetabolites are divided into three categories: antifolates, purine analogs and 
pyrimidine antimetabolites. They then operate to inhibit the development of the most 
rapidly proliferating cells in the body (e.g. bone marrow, gastrointestinal tract, etc.). 
Antifolate antimetabolites: They produce both the first striking remissions in leukemia (25) 
and the first cure of solid tumor, choriocarcinoma.  
 
1.7.4.1. Methotrexate 
 
History of clinical use: Metotrexate (Scheme 1.1), a folate antimetabolite synthesized five 
decades ago, has been in clinical use for more than 35 years. It has a long history of use 
in treatment of various immunologic diseases. MTX began as a drug for cancer treatment, 
particularly childhood leukemia, in the early 1940s (26). In the 1960s it was used for the 
treatment of rheumatoid arthritis and psoriasis. In the mid-1980s (27) many 
rheumatologists reported their experiences with MTX use in studies of rheumatoid 
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arthritis. Guidelines for MTX use were developed to address dosing, liver biopsy and 
monitoring strategies, which were aimed at reducing the incidence of adverse effects (28). 
Currently, methotrexate is indicated for the treatment of acute lymphocytic leukemia 
(ALL), as well as for rheumatoid arthritis and psoriasis. The drug has also been found 
efficacious in treatment of other diseases, including asthma, systemic lupus 
erythematosus, Crohn’s disease, myositis, vasculitis and ectopic pregnancy (29, 30). 
 
Mode of action: The passive diffusion of MTX through cell membrane is limited, due to 
its hydrophilic nature. Indeed, MTX is highly polar; and owing to this polarity, at the 
nearly neutral pH of biological fluids, it is present mainly in the doubly anionic species 
form. This leads to inhibition of cell penetration. As a consequence, only a small portion 
of MTX successfully enters the intracellular space by passive diffusion while the major 
portion enters by carrier-mediated mechanism. The main pharmacological target of action 
of MTX is the competitive inhibition of dihydrofolate-reductase (DHFR), an intracellular 
enzyme which reduces folic acid to tetrahydrofolate cofactors, which are in turn key 
intermediates in several important biochemical pathways.  Among these are the de novo 
biosynthesis of purines and of thymidylate. Mathews et al. (31), using Raman spectra of 
the MTX-DHFR complex, showed that the inhibition occurs as result of ionic binding 
between the N-1 of the pterin portion and the enzyme. Lack of reduced folates, purines 
and thymine in actively proliferating cells, such as those of the tumors, leads to a 
blockage of DNA and RNA synthesis, and eventually to cell death. 
 
 
Scheme 1.1: Structure of Methotrexate (MTX)  
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1.7.4.2. Folic acid 
 
Folic acid, or pteroylglutamic acid, consists of a pteridine that is linked to para-
aminobenzoic acid (PABA) and glutamic acid (Scheme 1.2). 
 
Physiological role: As a pharmaceutical product, folic acid (FA) is a vitamin, a 
nutritional supplement, and a diagnostic aid in folate deficiency (32). Folic acid, referring 
to the folate form, is a well-known water-soluble vitamin of the B-complex. It is mainly 
evolved from natural sources, but as it is available in small quantities in biological 
material, worldwide efforts are focused on its development and synthesis. The 
pharmaceutical product is chemically synthesized, and the L-enantiomer is the 
biologically active form. Folic acid is involved in many metabolic mechanisms leading to 
the synthesis of DNA and normal erythropoiesis. In intestinal cell, FA is mostly reduced 
to tetrahydrofolate (H4folate), the active form of this vitamin in a two-step reaction, 
which is catalyzed by the enzyme folate reductase. Inhibitors of this enzyme, like MTX, 
act as antifolate. Scheme 1.3 depicts the fate of folic acid in the biological environment. 
 
 
Scheme 1.2: Structure of folic acid 
 
H4folate functions as a coenzyme, a carrier of various activated one-carbon units in 
metabolic reactions. Folic acid and vitamin B12 metabolic pathways intersect at the 
conversion of homocysteine to methionine. FA is also proven to be completely 
ineffective (33) against any type of cancerous disease. However, it is also known to impact 
deeply on cancer development. Indeed, folate deficiency appears to play a crucial role in 
early cervical carcinogenesis by facilitating genetic modification at a fragile 
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chromosomal site (34). Folic acid plays a crucial role in DNA synthesis, where it enables 
cells to replicate normally.  
 
Mechanism of intracellular uptake: Folic acid is transported into cells either through a 
receptor-mediated endocytosis (35) facilitated by the folate receptor, or with the help of 
carrier proteins, such as the reduced folate carrier (RFC). The membrane-associated 
folate receptor is known to be overexpressed on the surface of a variety of human tumor 
cells, including cancers of the ovary, colon, kidney, uterus, tests, brain, lung, breast, and 
myelocytic blood cells, while it is highly restricted in most normal tissues (36). 
 
 
Scheme 1.3: Two-step conversion of folic acid to the active tetrahydrofolate by the 
enzyme folate reductase and its inhibition by methotrexate 
 
 1.7.5. Toxicity of Carbon nanotubes  
 
Generally, the harmful effects of nanoparticles arise from the combination of various 
factors, two of which are particularly important: (a) the high surface area, and (b) the 
intrinsic toxicity of the surface (37). In contrast with conventional particles of larger mean 
diameter, nanoparticles under 100 nm can potentially be more toxic to the lung (portal of 
entry), can redistribute from their site of deposition, can escape from the normal 
phagocytic defences and can modify the structure of proteins. Therefore, nanoparticles 
can activate inflammatory and immunological responses and may affect the normal tissue 
function (38). CNTs, in the context of toxicology, can be classified as ‘nanoparticles’ due 
to their nanoscale dimensions, therefore unexpected toxicological effects upon contact 
with biological systems may be induced. The nanometer-scale dimensions of CNTs make 
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quantities of milligrams possess a large number of cylindrical, fibre-like particles, with a 
concurrent very high total surface area. This total surface area will also depend on their 
degree of bundling and aggregation of nanotubes in solution. Note that the intrinsic 
toxicity of CNTs does not depend on the degree of surface functionalization and the 
different toxicity of functional groups. Batches of pristine CNTs (non-purified and/or 
non-functionalized) readily after synthesis contain impurities such as amorphous carbon 
and metallic nanoparticles (catalysts: Co, Fe, Ni and Mo). 
 
1.7.6. Biocompatibility of carbon nanotubes 
 
Despite the evidence of CNTs cytotoxicity, there have also been a number of published 
studies into CNT-based biomaterials, which support the biocompatibility of CNTs and 
CNT-based materials. This section gives a detailed discussion of investigations into 
interactions between CNT-based materials, neutral cells, osteoblasts, fibroblasts, 
antibodies and the immune system, ion channels and cellular membranes. 
 
Functionalization of CNTs has been used to address the problem of CNTs insolubility in 
aqueous media and, in many cases, has permitted linking of biologically active peptides 
and medicinal drugs to the CNTs side-wall (39, 40). These properties have generated 
interest in using CNTs as drug or vaccine delivery vehicles and to this end there have 
been several studies conducted on CNTs functionalization with vaccine or drug 
molecules (41,  42). 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1.    Polymers as Drug carriers 
 
The control of drug release in cancer through therapeutic systems is more advanced in 
modern pharmaceutical technology (43, 44). Rising interest in this ground sorts out, on the 
one hand from the often unsuccessful research for effective and non-toxic new drugs, and 
on the other hand from new knowledge of the biochemical events around and inside 
tumor tissues. In fact, the active agent is spread over the entire body and reaches not only 
the target cells or tissues but also interacts with healthy cells. This results in the 
peripheral toxicities and low therapeutic efficiency, and prompts the search for novel 
therapeutic strategies. The enhancement of drug delivery systems has been necessary, 
including drug-antibody conjugates (immunoconjugates), conjugates obtained by linking 
drugs to natural or synthetic polymers (macromolecular prodrugs) (45, 46), vesicular or 
particulate systems (liposomes (47), nanoparticles (48), microparticles for regional therapy 
(49)) and polymeric implants (50). Unfortunately some of these systems have often 
disappointed early expectations. In the case of immunoconjugates, the inefficacy was 
mainly due to the limited access of these relatively big molecules into tumor mass, the 
heterogeneity of tumor cells and the different humeral response among patients (51). 
Therefore, a strong interest was developed in the potentially promising systems, and 
water-soluble carriers covalently linked to the drug through a biodegradable spacer 
constitute one of them.  
 
2.1.1. Requirements for polymeric drug carrier 
 
There are two types of polymers to be used as drug carriers: the natural and the synthetic 
macromolecules. They must operate by aiming to maximize their potential as polymeric 
drug carriers by decreasing the toxicity, and (or) increasing the therapeutic index of the 
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anticancer drug. Therefore they must meet certain requirements including 
hydrosolubility, biodegradability, biocompatibility, and chemical composition.    
 
2.1.1.1. Hydrosolubility 
 
Water solubility is an important requirement for any drug carrier, either polymer or 
carbon nanotubes intended to be used in the biomedical field. This will demand the 
polymer to be linear and highly flexible. Working with the polymer the entropy of the 
solution will increase, and therefore favour the dissolution process and the presence of 
intra-or extrachain hydrophilic entities such as hydroxyl- and amino-terminals. These 
hydrophilic entities are of excellent utility as they are capable of undergoing effective 
hydration. The ability to incorporate charged species into the polymer also leads to its 
hydrosolubility property. In addition, the application of poly(ethylene oxide) (PEO) in the 
polymer therapeutic field rose in interest, owing to its numerous properties such as the 
solubility in both aqueous and organic media, ease of chemical modification, and 
biocompatibility (52, 53), which are also imparted once PEO is incorporated into a polymer. 
 
2.1.1.2. Biodegradability 
 
The candidate carrier must be sufficiently large, this will be important for the hindrance 
of rapid excretion by kidneys observed with low molecular weight. The biodegradation 
and resultant catabolic elimination following drug release, will be possible through the 
composition of the backbone comprising segments amenable to hydrolytic and enzymatic 
cleavage.  Most biodegradable polymers are designed to degrade as a result of hydrolysis 
of the polymer chains into biologically acceptable, and progressively smaller, 
compounds. In some cases—as, for example, polylactides, polyglycolides, and their 
copolymers—the polymers will eventually break down to lactic acid and glycolic acid, 
enter the Kreb's cycle, and be further broken down into carbon dioxide and water and 
excreted through normal processes. Degradation may take place through bulk hydrolysis, 
in which the polymer degrades in a fairly uniform manner throughout the matrix. For 
some degradable polymers, most notably the polyanhydrides and polyorthoesters, the 
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degradation occurs only at the surface of the polymer, resulting in a release rate that is 
proportional to the surface area of the drug delivery system (54). 
In order to increase the biodegradability of a polymeric carbon backbone, the equipment 
of the latter with peptide, saccharide or nucleotide sequences is required, as they are 
recognized and biodegraded by numerous enzymes present in the lysosomal compartment 
of the cell. 
All of the previously described systems are based on polymers that do not change their 
chemical structure beyond what occurs during swelling. However, a great deal of 
attention and research effort are being concentrated on biodegradable polymers. These 
materials degrade within the body as a result of natural biological processes, eliminating 
the need to remove a drug delivery system after release of the active agent has been 
completed.  
2.1.1.3. Biocompatibility 
 
The polymeric backbone must be non-toxic, non-immunogenic, and non-thrombogenic in 
order to avoid any carrier-generated toxic, immunogenic, and blood-clotting side effects. 
When these requirements are unsuccessful it will result in premature destruction of the 
carrier through attack by the host defense systems, which renders the drug delivery 
system ineffective. PEO is found to be a promoter of cell fusion and hydration (55) as well 
as a chemical entity for reducing or controlling the antigenicity of immunogenic   
proteins (56). An earlier review article (57) stressed the conjugation of PEO to protein or 
liposome as an important tool for reducing the shortcomings encountered in using these 
therapeutic agents, namely the degradation by proteolytic enzymes, thermal instability, 
and immunogenicity. More recently it has been reported that the presence of PEO 
segments in polyelectrolyte causes complexation with plasmids, reducing the side effects 
and increases the lifetime of these complexes in vivo (58, 59) . 
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2.1.1.4. Chemical composition 
 
The carrier macromolecule must comprise reactive functional groups suitable for drug 
anchoring and release. The separation of these groups should be completed from the 
principal chain by short side chains or spacers. The presence of spacers will serve to 
diminish the steric inaccessibility due to the polymeric backbone. By their nature, the 
spacers should be stable in the bloodstream (60) but susceptible to either enzymatically 
catalyzed or pH-dependent hydrolysis in the lysosomal compartment (61). Polymeric 
carrier should equally develop the aptitude to be intended for predetermined cell types. 
This will be achieved by the incorporation of targeting moieties such as cationic 
functions and antibodies (62). The presence of cationic function, including tertiary amino 
groups, is required in the carrier backbone as this will facilitate adsorptive pinocytotic 
cell entry (63) and therefore prevent problems related to potential iconicity or polarity of 
the monomeric drug, and on the other hand, increase drug selectivity for the transformed 
cell, given that many types of cancer are characterized by negative surface charge. Also, 
the macromolecular carrier should incorporate an interposition between the spacer-
bearing units, of subunits lacking drug-binding abilities along the principal chain. This 
will prevent multifunctional drug binding by reducing spacer density in the molecule.   
 
2.1.2. Natural polymers as drug carriers 
 
The preparation of natural polymers may be restricted by the need for several purification 
steps, and their use is limited by their high immunogenicity. Nevertheless they have the 
advantage of easy availability and biocompatibility. Many of them have been identified 
and have been used as possible drug or possess an intrinsic anticancer activity. It has been 
noticed that albumin, bovine serum albumin (BSA), chitins, and dextran have been 
successfully conjugated to doxorubicin (64, 65) and mitomycin (66), respectively. In general, 
these polymers being biodegradable owing to their natural origin, they will be excreted 
from the bloodstream by natural catabolic mechanism. Nevertheless, their use as drug 
carriers is often limited. Indeed, the substitution of natural macromolecules with 
covalently linked low-molecular-weight drug molecules generally results in the 
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hampering of the host’s ability to enzymatically degrade the polymeric carrier effectively 
(67)
. The loss of biodegradation ability into easily eliminated fragments causes the 
resistance of elimination from the body. The administration of natural macromolecules 
has been inefficacious due to the main problem such as short intravascular half-life, 
immunogenicity, and sometimes poor solubility (68). In order to dramatically increase their 
therapeutic effectiveness, their modification with synthetic macromolecules is needed. 
 
2.1.3. Synthetic polymers as drug carriers 
 
The synthetic polymers operating as drug carriers must respond to the general 
requirement to be fulfilled by any polymer in an attempt to serve in biological 
environment (section 1.7.1.1), especially their entire molecular-weight distribution must 
be under the kidney threshold (30 000-50 000 KD) if they are not biodegradable. This 
will have the advantage of minimizing storage. Polymeric drug delivery systems are 
attractive as a means of effectively controlling drug concentration and targeting specific 
regions in the body. Until recently, most polymers investigated for drug-delivery 
applications were either linear (nonbranched) or crosslinked (highly branched in nature). 
Current advances in polymers with highly branched and defined architectures have 
opened new opportunities for developments within the drug-delivery field. These 
polymers are frequently referred to as being hyperbranched or dendritic to emphasize the 
role of branching in the polymer architecture. A variety of intriguing systems are being 
explored that exploit the potential of hyperbranched polymers for use as drug-delivery 
agents (69). 
Controlled drug delivery occurs when a polymer, whether natural or synthetic, is 
judiciously combined with a drug or other active agent in such a way that the active agent 
is released from the material in a predesigned manner. The release of the active agent 
may be constant over a long period, it may be cyclic over a long period, or it may be 
triggered by the environment or other external events. In any case, the purpose behind 
controlling the drug delivery is to achieve more effective therapies while eliminating the 
potential for both under- and overdosing. Other advantages of using controlled-delivery 
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systems can include the maintenance of drug levels within a desired range, the need for 
fewer administrations, optimal use of the drug in question, and increased patient 
compliance. While these advantages can be significant, the potential disadvantages 
cannot be ignored: the possible toxicity or nonbiocompatibility of the materials used, 
undesirable by-products of degradation, any surgery required to implant or remove the 
system, the chance of patient discomfort from the delivery device, and the higher cost of 
controlled-release systems compared with traditional pharmaceutical formulations.  
Note that the synthetic polymers are categorized according to the chemical nature (e.g. 
polysaccharides, vinylic, acrylic polymers, poly(amino acids), etc.), the stability of the 
backbone, and the molecular weight. More interest was developed in the use of the 
synthetic polymers as drug carriers since Rigsdorf (70) proposed his model of water-
soluble macromolecule prodrugs in the mid-Seventies. In the following text it has been 
found out whether, and to what extent, these prerequisites are met in the structural 
compositions of the three selected carrier types (1) the α,β-DL-polyaspartamides, (2) the 
poly(amidoamines), and (3) the 2-hydroxypropyl-methacrylate polymers (HPMA). In 
addition, polyamides obtained by polycondensation processes will cursorily be discussed 
because of their sporadic use as carriers.    
2.1.3.1. α,β-DL-polyaspartamides 
This carrier type has been exalted into recognition of polymer research some three 
decades ago (71, 72). It can be synthetically prepared by high-temperature condensation 
polymerization of DL-aspartic acid in orthophosphoric acid medium, leading to a 
polysuccinimide intermediate (Scheme 2.1).  
 
Scheme 2.1: Synthesis of polysuccinimide (PSI) 
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In the following polymer-homologous reactions suitably performed in a dipolar aprotic 
solvent such as N,N-dimethylformamide, the intermediary polysuccinimide is treated 
sequentially with amine nucleophiles (NH2-R1, NH2-R2); occasionally a third amine, 
NH2-R3, may be employed in this operation, whereby amide ring opening gives rise to 
the generation of the ultimate polyaspartamides (73, 74). These linear polyamides are 
composed of randomly distributed aspartamide repeat units bearing N-attached 
substituents (R1, R2, etc.) as introduced by the amine nucleophiles chosen. Scheme 2.2 
depicts this sequence of ring opening steps (75). 
 
Note that here and in subsequent polyaspartamide representations, only the α-peptidic 
forms are shown for convenience, although the isomeric β-forms, with two carbon atoms 
(rather than one only) separating –CO and NH-, are also present. 
 
The structural arrangement in scheme 2.2 was made by substituting a solubilizing entity S 
for NH-R1, a homing device H for NH-R2, and a drug-binding functional group F for 
NH-R3 (Scheme 2.3). 
 
It should certainly result from the thorough discussion in the previous structure-function 
relationships that polyaspartamides complying with this schematic representation will be 
able to provide an excellent “workhorse” service in drug conjugation studies. Purposely, 
the following hold (Schema 2.3): (i) The vital prerequisite of water solubility will be 
afforded by the numerous freely rotating aliphatic main-chain bonds and, in particular, by 
the extrachain S units chosen so as to contain tert-amine, hydroxyl, or, perhaps, 
oligo(ethylene oxide) groups (76). These functionalities will be prone to equation, that is, 
hydrogen bond formation with the aqueous solvent, and/or protonation with generation of 
cationic sites. (ii) Steric accessibility of the anchoring site F is optimized by insertion of a 
suitably long (say, 8-10 atomic constituents) aliphatic spacer link between F and 
backbone, thus reducing any steric hindrance potentially provided by the main chain 
proper. (iii) The chain construction has been rendered nontoxic through use of aspartic 
acid as the principal molecular backbone source. (iv) The chain is biodegradable 
hydrolytically at the CO-NH link for catabolic fragment elimination through the globular 
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system of the kidneys upon drug release. A vital detoxification process in light of the fact 
that, as mentioned before, large nondegradable macromolecules, such as vinyl-type 
polymers and other carbochain macromolecules strongly resist excretion and tend to 
induce toxicity. Such backbone degradation must be slow and controlled, however, so as 
to ensure stability during serum exposure, yet fragmentation in the endosomal 
compartment. In the polyaspartamide structure, these conditions are ideally met: in the 
serum environment (pH~7.5) only minimal hydrolytic CO-NH bond fission is observed, 
whereas in the endosomal space (pH~5) such fragmentation proceeds as expected, albeit 
slowly. The superimposition on hydrolytic bond fission is the process of enzymatic bond 
breaking effective both at main-chain NHCO sites and, to a variable extent, also at drug-
binding links. Whereas natural polypeptides are prone to rapid degradation (unzipping) as 
a consequence of α-peptidase activity in the serum, such unzipping is grossly impeded by 
the presence of D-configured CH groups and β-peptide units in the chain that are inert to 
α-peptidase attack (77). 
 
   Scheme 2.2: Amide ring opening process for polyaspartamide  
 
Scheme 2.3: Substitution of a solubilizing entity S, a homing device H and a drug-
binding functional group F to polyaspartamide  
 
2.1.3.2. Polyamidoamides 
 
Poly(amidoamines) (PAAs) belong to the family of polymers characterized by the regular 
arrangement of amido groups and secondary (or/and tertiary) amines along the 
macromolecular chain. Pioneered by Ferruti (78), they are synthesized by polyaddition of 
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primary monoamines or bis(secondary amines) to bisacrylamides. Since they bind tightly 
to heparin, PAAs were introduced in biomedical application; initially as a heparin-
adsorbing surface for medical devices (heparin renders the device non-thrombogenic) (79). 
PAAs were later proposed as particularly promising drug and DNA (80) delivery carriers 
owing to their water solubility, biodegradability (81), conformation-changing ability with 
changing pH (82), and potentially low cytotoxicity compared with other synthetic 
polymers, e.g. poly-L-lysine. Furthermore, PAAs are also known to possess structure-
cytotoxicity relatioships. They have both aminic and amidic sites in their backbones, and 
the polymers prepared are generally selected to incorporate several different variables to 
reinforce the aforementioned physicochemical properties. Using the pKa values different 
PAAs, Ferruti(83) demonstrated the basicity of aminic nitrogen atoms of each repeating 
unit to be independent of the degree of protonation of the whole macromolecule. Thus, 
the main influence on polymer basicity is governed by the aminic moiety; therefore 
several different monoamines were incorporated. The purpose of monoamine 
incorporation was to ensure firstly, higher basicity, as the mechanism of macromolecule 
cell entry, endocytosis, exposes the monoamine to pH changes, from pH 7.4 extracellular 
to pH 5.5-6.5 within the endosomal-lysosomal system (84), and secondly, increased water 
solubility. More recent review article from Ferruti’s laboratory cover the synthesis of 
primary amine-functionalized PAAs (85), the biomedical applications (86) and the 
correlation between physicochemical and biological properties (87). 
 
2.1.4. Polymer-drug conjugation 
 
The drug systems investigated in this project have been the conjugation of 
copolyaspartamides as polymeric carriers by varying the molecule rate of solubilizing 
group and anchoring drug respectively. Thus, the conjugation is achieved by formation of 
either ester or amide biocleavage bond. Since Folic acid and methotrexate represent the 
same chemical property, the investigation made on polymers-bound folic acid can result 
to the conclusion of polymers-bound methotrexate.  
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2.1.4.1. Polymer-MTX conjugation 
 
Aiming to improve its therapeutic index, including the site-specific targeting or proving 
controlled release, MTX has been conjugated to biopolymers like mono-and polyclonal 
antibodies (88, 89), serum albumins (90, 91), neoglycoproteins (92), chitosan (93). The 
conjugation of MTX to synthetic polymers has been extensively reported (94, 95). These 
reports include investigation from this laboratory. Indeed, following Ringsdorf’s model 
of macromolecular prodrugs, MTX was conjugated with various polymeric carriers. In 
earlier project (96) polyaspartamides were conjugated with MTX through tethers 
containing an ester group as the biofissionable site, and in recent study (97) series of 
related conjugates were prepared with biocleavage carboxamide links in the connecting 
spacer. 
 
2.1.4.2. Polymer-folic acid anchoring 
 
The potential use of cellular nutrients for macromolecular and colloidal particle uptake is 
appealing, since receptor-mediated endocytosis is a cellular process designed for 
transporting critical molecules across the plasma membrane into the cytoplasm (98).  
Rapidly-dividing cells express high affinities for folic acid because folate is an essential 
factor in purine, nucleotide, and DNA synthesis. Hence, the possibility of utilizing this 
pathway for promoting folate-linked molecules or colloidal particles to enter 
gastrointestinal (GI) epithelia. By virtue of its ability to be taken up by folate receptor 
overexpressed on certain tumor cells, folic acid has been widely investigated as a 
targeting molecule for active anticancer drug delivery. Proper synthesis procedures have 
been pointed out to link folic acid to drug carriers to produce targeting drug delivery 
systems. The folic acid molecule possesses two carboxyl groups, termed α-and γ-
carboxyl group, which can act as handles for covalent attachment. However, according to 
literature, there is a stronger affinity of folate toward its receptor, when linked via the γ-
carboxyl derivatives are not readily recognized (99).                                                      
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Folate-induced receptor-mediated endocytosis has been extensively exploited to facilitate 
entry of anchoring drugs (100), antibodies (101), imaging agents (102), liposomes (103) or 
macromolecules (104), and proteins into cells. Folate-conjugated proteins present the 
advantages of conceivably contacting and binding to all cells in a culture medium 
simultaneously. This avoids a natural vitamin endocytosis pathway. Unlike hormone- or 
virus-mediated endocytosis, folate uptake occurs in all dividing cells, at reasonable rates, 
and folate is deposited into cytosolic rather than lysosmmal compartments (105). 
 
2.2.     Carbon nanotubes as Drug carriers 
 
Nanotechnology is expected to influence all current industries including semiconductors, 
manufacturing and biotechnology, and it may also create several new ones. Major 
challenges remain, before to take these opportunities to the realization. Some of 
opportunities include the ability to assemble, characterize and manipulate materials at the 
nanoscale level. Nanomedicine is an area with particular promise and may inspire the 
construction of nanostructured carriers for the targeted delivery of small-molecule 
‘passengers’ to a desired area. Nanosized delivery vehicles may also offer better or more 
efficient use of an active molecule (i.e. drugs, antigens, proteins, enzymes and nucleic 
acids) by controlling release rates, by protecting it from unwanted metabolic processes or 
through targeted delivery processes that can reduce side effects. A drug delivery system 
is usually designed to improve the pharmacological and therapeutic properties of 
conventional drugs and to overcome problems such as limited solubility, poor 
distribution, lack of selectivity and tissue damage. Cell membranes act as barriers and 
allow only certain structures with the right hydrophilicity to hydrophobicity ratio to pass. 
Among the currently available delivery systems, which include liposomes, emulsions, 
polymers and microparticles (106), carbon nanotubes (CNTs) have recently gained 
popularity as potential drug carriers of therapeutic agents and diagnostic tools (107). They 
have nanoscale dimensions, and can be modified through covalent bonding of functional 
organic molecules. CNTs have been shown to penetrate easily through cell membranes, 
have been proposed as components for DNA and protein biosensors, ion channel blockers 
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and as bioseparators and biocatalysts (108). CNTs have also been used as platforms to 
detect antibodies associated with human auto-immune diseases. 
 
2.2.1. Carbon nanotubes 
 
Carbon nanotubes (CNTs) are interesting new molecular forms of carbon in the fullerene 
family, discovered by Iijima (109). Due to unique electronic and mechanical properties of 
CNTs (110) and also their resistance to acid/basic media (111) they have attracted a special 
attention.  
 
CNTs can be imaginatively produced by rolling up a single layer of graphene sheet 
(single-walled CNTs; SWNTs) (112, 113), or by rolling up many layers to form concentric 
cylinders (multi-walled CNTs; MWNTs) (114). As-produduced CNTs, both SWNTs and 
MWNTs, are commercially available, with different details and degrees of purity. Pristine 
CNTs are completely insoluble in all solvents, which has generated some health 
concerns; consequently, their biological properties are being studied in terms of     
toxicity (115). The development of efficient methodologies for the chemical modification 
of CNTs has stimulated the preparation of soluble CNTs that can be employed in several 
biological applications, among which drug delivery appears to be particularly    
promising (116, 117, 118, 119). 
 
However, the hydrophobic and inert nature of the surface of as-prepared nanotubes is 
unfavorable for these applications (120). In order to improve the interaction of CNTs and 
foreign molecules it is necessary to modify the surface of the nanotubes. This manner of 
modifying the surface of nanotubes results in the functionalization of carbon nanotubes.     
 
2.2.1.1. Synthesis of Carbon nanotubes (CNTs) by Chemical Vapor deposition 
(CVD)  
                                                                                                                                  
Chemical Vapor Deposition (CVD) is a versatile technique often used in the 
semiconductor industry for deposition of materials on various substrates. In the CVD 
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process, a gas or vapor precursor is transformed into solids, such as thin films, powders, 
or various structured materials, inside a reactor. Chemical vapor deposition has also been 
used for many years to produce carbon fibers, filaments, and tubular carbon materials. 
Recently, CVD has been used to synthesize a variety of nanostructured materials, 
including carbon nanotubes and nanowires composed of various materials, as well as 
graphene and thin films. It is an inherently scalable method, providing an important path 
from research to production.  
 
The development of the Chemical Vapor Deposition (CVD) method used to produce 
carbon nanotubes, has enabled the synthesis of high quality carbon nanotubes that grow 
in specified locations and with greater purity. Carbon nanotubes can be grown by CVD 
directly onto substrates or onto bulk-supported catalysts. The process typically consists of 
flowing a carbon feedstock, over a catalyst-covered substrate at elevated temperature; the 
feedstock molecules decompose upon the catalyst, releasing their carbon to form 
nanotubes. Advantages of using the CVD process for nanostructure synthesis include: 
 
2.2.1.2. Comparison of CVD to Other Methods Used to Make Nanotubes 
 
A  CVD 
Chemical vapor deposition (CVD) has been found to provide a number of benefits over 
other nanostructure synthesis methods. Nanotubes are obtained at relatively low 
temperatures with high quality and purity. The comparatively simple process can provide 
nanotubes of long length and controllable diameter. Catalyst deposition on substrates 
allows for formation of novel structures. In addition, the CVD method is scalable to 
industrial production levels (121).    
 
B Arc Discharge  
In the arc discharge method, nanotubes are found in soot produced in arc discharge with 
catalytic metals (e.g. Fe, Ni, Co). Two graphite rods, separated by a few millimeters, are 
connected to a power supply. At 100A, carbon vaporizes and forms hot plasma (122).  
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Unlike CVD, in arc discharge, it is generally difficult to control the location and 
alignment of nanotubes. The resultant nanotubes are produced in small quantities, often 
short with random sizes and orientations, and typically tangled, making some 
applications difficult. The method requires evaporation of carbon atoms from solid 
targets at very high temperatures and the products generally require purification (123).  
C. HiPco (High Pressure Carbon Monoxide Conversion)                                                       
In the HiPco method, high pressure carbon monoxide (CO) is heated with a volatile 
catalyst precursor (e.g. Fe(CO)5) at high temperature. The SWNT form in the gas phase 
and are removed by filter from flowing, recirculating CO (124). 
Unlike CVD, the HiPco method requires pressurized carbon monoxide, very high process 
temperatures, and a metal catalyst that is difficult to remove at the end of a process (125).  
D. Laser Ablation or Vaporization                                                                                  
In the laser ablation method, nanotubes are produced by pulsed YAG laser ablation of a 
graphite target in a furnace at temperatures near 1200°C. The target is hit with intense 
laser pulses, generating carbon gas from which the nanotubes are formed (126). 
Unlike CVD, in the laser ablation method, it is difficult to control the location and 
alignment of the nanotubes produced. Small quantities of nanotubes result from this 
process and they are generally tangled, making some applications difficult. The method 
also requires evaporation of carbon atoms from solid targets at very high        
temperatures (127). 
2.2.2. Functionalization of Carbon nanotubes for biological applications 
 
As produced, raw carbon nanotubes have highly hydrophobic surfaces, and are not 
soluble in aqueous solutions. To overcome the problem of poor processabilty, the 
functionalization and solubilization of CNTs have received much recent attention. For 
biomedical applications, surface chemistry or functionalization is required to solubilize 
CNTs, and to render biocompatibility and low toxicity. The functionalization generates 
functional groups at the surfaces of CNTs. These functional groups could react with other 
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chemicals, prepolymers and polymers, and give rise to a homogeneous dispersion or 
solubilization of CNTs. Surface functionalization of carbon nanotubes may be covalent or 
noncovalent. Chemical reactions form bonds on nanotube sidewalls resulting into 
covalent functionalization, while noncovalent functionalization exploits favorable 
interactions between the hydrophobic domain of an amphiphilic molecule and the CNT 
surface, affording aqueous nanotubes wrapped by surfactant.   
 
Thus chemical functionalization plays an essential role in tailoring the properties and 
application versatility of CNTs. The requirement is that the functionalized carbon 
nanotubes have to exhibit: - high propensity, - biocompatibility, -solubility, - excretion, - 
little toxicity. 
 
2.2.2.1. Covalent functionalization of carbon nanotubes 
 
The covalent functionalization of CNTs is the alternative and extremely promising 
approach for applications in fields such as that of functional and composite materials and 
that of biology. According to the location of the functional groups, two main strategies 
are used to covalently functionalize CNTs with biomolecules: (i) defect functionalization, 
and (ii) sidewall functionalization (128, 129). 
 
A. Defect functionalization                                                                                        
Various covalent reactions have been developed to functionalize carbon nanotubes, 
oxidation being one of the most common. CNT oxidation is carried out with oxidizing 
agents such as nitric acid (130, 131). During the process, carboxyl groups are formed at the 
ends of tubes as well as at the defects on the sidewalls. Zeng et al. observed sp3 carbon 
atoms on SWNTs after oxidation and further covalent conjugation with amino acids (132). 
Permanganate is a well known oxidizer in organic chemistry (133). Potassium 
permanganate has been used as the oxidant in the presence of sulfuric acid to 
functionalize CNTs (134). It is also used along with a phase transfer catalyst (135). Other 
oxidants used to functionalize CNTs are concentrated nitric acid (136, 137) and concentrated 
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sulfuric acid as the oxidant (138). This procedure of functionalization of CNTs generates 
mainly the –OH and –COOH functional groups, more easily at the caps than at the walls. 
By utilization of such functional groups, it is possible to attach CNTs to various 
polymeric agents and then to make them soluble in organic solvents (139, 140). 
Chemical treatments, such as strong oxidizing acid mixtures of HNO3/H2SO4 under 
sonication, modify CNT surfaces with anchor groups, including carboxylic, carbonyl and 
hydroxyl functions, eventually used to covalently connect molecules to the tubes 
(Scheme 2.4). The carboxylic acid groups are often the most common choice to connect 
the CNTs with the amino-terminated sites present on the biomolecules. Before covalent 
modification, the carboxylic acids are often activated by thionyl or oxalyl chloride, 
carbodiimides or active esters, to get highly reactive intermediate groups, to link different 
types of biomolecules to CNTs via stable covalent bonds. The carboxyl groups of CNTs 
were activated, for example, in the presence of N-hydroxysuccinimide and carbodiimide. 
This can facilitate the conjugation of peptide nucleic acid (PNA, an uncharged DNA 
analogue) to the end of CNTs via a stable amide bond. PNAs were then hybridized with 
complementary DNA sequences, showing the possibility of recognition-based assembly 
and the potential use as biological sensors. Similar methods based on the amide linkage 
were used to immobilize DNA (141). In this research the carboxyl groups of CNTs were 
activated in the presence of 2-(1H-benzotrial-1-yl)-1,1,3,3-tetramethylurium 
hexafluorophosphate (HBTU). They showed that aqueous solubility can be assured by a 
covalent attachment of hydrophilic moieties. 
          
 
Scheme 2.4: f-CNTs with Sulphuric acid and Nitric acid 
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B. Sidewall Functionalization 
This type of covalent functionalization is based on the addition reactions to CNTs. By 
exploiting the chemistry of fullerenes, 1,3-dipolar cycloaddition of azomethine ylides, 
aryl diazonium salt addition or reductive alkylation using lithium and alkyl halides have 
been successfully employed to CNTs (142, 143, 144, 145, 146). Such direct sidewall modification 
of CNTs permits the incorporation of different functional groups on the nanotube which 
could be further derivatized (147). The covalent bond presents the advantage of being more 
robust during manipulation and processing in comparison to the noncovalent dispersion. 
Nevertheless, both covalent and noncovalent functionalization of CNTs have been 
exploited for application of such materials in the field of drug delivery.  
 
2.2.2.2. Noncovalent functionalization of carbon nanotubes 
 
Compare to covalent functionalization, noncovalent functionalization of CNTs can be 
modified with amphiphilic surfactant molecules or polymers. The noncovalent dispersion 
of CNTs in a solution allows preservation of their aromatic structure and thus their 
electronic characteristics. The dispersion procedures usually involving ultrasonication, 
centrifugation and filtration are quick and easy. Since the chemical structure of the π-
network of carbon nanotubes is not disrupted, except for shortening of length due to the 
sonication employed in the functionalization process, the physical properties of CNTs are 
essentially preserved by the noncovalent approach. Hydrophobic or π-π interactions often 
evoked as likely responsible for noncovalent stabilization. Consequently, aqueous 
solution of CNTs, especially SWNTs, engineered by noncovalent functionalization are 
promising for multiple biomedical applications, including imaging.  
An ideal noncovalent functionalization coating on CNTs for biological applications 
should have the following characteristics. First, the coating molecules should be 
biocompatible and non-toxic. Second, the coating should be sufficiently stable to resist 
detachment from the nanotubes surface in biological solutions, especially in serum 
having high salt and protein contents. The amphiphilic coating molecules should have 
very low critical micelle concentrations (CMC) value so that the nanotubes coating is 
stable, after removal of most of the excess coating molecules from CNT suspension. 
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Lastly, the coating molecules should have functional groups which are available for 
bioconjugation with antibodies or other molecules to create various functional CNT 
conjugates for different biological applications. The polyaromatic graphitic surface of 
carbon nanotube is accessible to the binding of aromatic molecules via π-π stacking (148, 
149)
 Chen et al. showed that proteins can be immobilized on SWNTs by an amine-reactive 
pyrene derivative (150) Wu et al. also used pyrene conjugated glycodendrimers to 
solubilize carbon nonotubes (151)  
  
Nowadays, three classes of molecules are mainly used for CNTs dispersion. Surfactants 
are used because they are easily available and low-cost. Polymers and biopolymers 
(nucleic acids and peptides) are also very efficient in the dispersion process. 
 
A. Surfactants                                                                                                                                                                                                                                 
A series of anionic, cationic and nonionic surfactants have been proposed to disperse 
nanotubes. Sodium dodecyl sulfate (SDS) and Triton X-100 were used to obtain CNTs 
suspensions up to 0.1 and 0.5 mg/mL, respectively (152). However, the stability of this 
suspension was not longer than one week. A better result was obtained by using sodium 
dodecyl-benzene sulfonate (SDBS), which was able to provide stability over one month 
reaching 10 mg/mL concentration of the suspension. The combination of π-π interactions 
of aromatic moieties between CNTs and SDBS and the long lipid chains of the SDBS 
increases the stability of the complex. Atomic force microscopy (AFM) and electronic 
transmission microscopy (TEM) studies of SDS/CNTs dispersions showed that CNT are 
mainly present as individual tubes uniformly covered by the surfactant (153).  
 
Various amphiphiles have been used to suspend carbon nanotubes in aqueous solutions, 
with hydrophobic domains attached to the nanotube surface via van der Waals forces and 
hydrophobic effects, and polar heads for water solubility (154). Carbon nanotube 
solubilized by those amphiphiles with relatively high critical micelle concentrations 
(CMC), are typically unstable without an excess of surfactant molecules in the solution. 
Large amounts of surfactants may lyse cell membranes and denature proteins, and are 
therefore not useful in biological environments. 
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B. Polymers                                                                                                              
Polymers are widely used, for example as molecular carriers for drug delivery (155). In the 
solubilization of CNTs they represent a good alternative to surfactants, although they do 
not have a better dispersion efficiency (156). The mechanism of dispersion is based in this 
case on wrapping of the polymer around the tubes. The polymer wraps around ropes of 
nanotubes (Figure 2.1). The driving force of the phenomenon is likely to be the steric 
repulsion of the polymer. Once the polymer is attached to the surface of the nanotubes, it 
offers a sufficient repulsive potential stabilizing the dispersion (157). In the case of 
nonionic polymers, based on poly(oxyethylene) copolymers, the efficiency of the 
dispersion is instead due to their hydrophilic counterpart. For particularly high molecular 
weight polymers, the suspendability is enhanced as the steric stabilization is increased by 
a wider coverage of the surface. In a similar approach, CNTs were dispersed by using 
cationic copolymers (158). The nanotubes were covered by the hydrophobic backbone of 
the polymer while the positive tetraalkylammonim groups were exposed at the surface to 
display water solubility. These types of fluorescent polymers have also been employed to 
study the interaction with mammalian cells. Poly(vinylpyrrolidone) was conjugated with 
various fluorescent dyes. CNTs were suspended in 1% SDS and mixed with the 
florescent polymers to form supramolecular complexes, which were found to have 
potential applications as new molecular probes (159). With respect to have a polymer 
which can easily present a peptide group after opening ring process by different amines, 
polysuccinimide has been chosen in this research as polymer coating of the carbon 
nanotubes for noncovalent functionalization. 
 
 
Figure 2.1: Coating of CNTs with polymer 
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C. Biopolymers 
The solubilization of CNTs with biological components is certainly more appropriate 
towards integration of this new type of material with living systems. Self-assembly 
processes similar to π-π interactions typical of double-stranded DNA can be exploited, 
for example to disperse the nanotubes. Nucleic acids are certainly ideal candidates to 
form supramolecular complexes based on π-stacking between the aromatic bases and the 
CNTs surface. Indeed, Zeng et al. (160, 161) have described an easy way to solubilize 
carbon nanotubes by simple sonication in the presence of a single-strand DNA. A 
molecular modeling study was perfomed to explain the formation of the hybrids exerted 
by DNA wrapping and subsequent CNTs debundling. The DNA-nanotube complexes 
displayed solubility in the range of mg/ml, and their good stability permitted the 
purification using ion-exchange chromatography. Amphiphilic peptides belong to another 
class of biopolymers that efficiently disperse CNTs (162). The presence of amino acids like 
tryptophan, phenylalanine, tyrosine and histidine into peptide sequence plays a key role 
on the solubilization process in water. These peptides could be selected from phase-
display peptide libraries (163) or by design (164, 165). The design of highly specific peptides 
to wrap around the nanotubes represent an interesting way to assure solubility and may 
even provide a useful tool for size-separation. More recently, cyclic peptides were also 
proven to have similar capabilities (166). 
 
2.2.3. Application of CNTs in drug delivery 
 
2.2.3.1. Peptide delivery by CNTs 
 
The application of CNTs has been investigated as template for presenting bioactive 
peptides to the immune system (167). For this purpose, a B-cell epitope of foot-and mouth 
disease virus (FMDV) was covalently attached to the amine groups present on CNTs, 
using a bifunctonal linker. The peptides around the CNTs adopt the appropriate 
secondary structure for recognition by specific monoclonal and polyclonal antibodies. 
The immunogenic features of peptide-CNTs conjugates were subsequently assessed in 
vivo (168). Immunization of mice with FMDV peptide-nanotube conjugates elicited high 
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antibody responses as compared with the free peptide. These antibodies were peptide-
specific since antibodies against CNTs were not defected. In addition, the antibodies 
displayed virus-neutralizing ability. The use of CNTs as potential novel vaccine delivery 
tools was validated by interaction with the complement (169). The complement is that part 
of the human immune system that is composed of a series of proteins responsible for 
recognizing, opsonising, clearing and killing pathogens, apoptotic or necrotic cells and 
foreign materials. Salvador-Morales et al. (170) showed that pristine CNTs activate the 
complement following both the classical and the alternative way by selective adsorption 
of some of its proteins. Because complement activation is also involved in immune 
response to antigens, this might support the enhancement of antibody response following 
immunization with peptide-CNTs conjugates.     
    
2.2.3.2. Methotrexate delivery by CNTs 
 
To maximize the efficacy of a drug, the choice of the delivery system is of fundamental 
importance. Conventional drug administration often fails due to low drug solubility-
instability in biological medium, poor distribution among the cells and lack of selectivity 
and damage of healthy tissues. Drug delivery systems are aimed to minimize the 
degradation, to increase its bioavailability, to target it to specific cells and to reduce the 
amount of drug need, deceasing toxicity and harmful side effects. CNTs possess an 
enormous aspect ratio (between length and the diameter) compared to classical drug 
delivery systems such as liposomes or polymer-based carriers, and are becoming a 
promising alternative in this field, since the first demonstration of their capacity to 
penetrate into cells. CNTs can be functionalized with antibiotics to deliver them into the 
cells.  
 
Note that methotrexate (MTX) is a well-known and potent anti-cancer agent, used also to 
cure autoimmune disease (171). However, MTX suffers low bioavailability and toxic side 
effects (172). Therefore, an increased bioavailability and a targeted delivery are highly 
desirable. Being a drug widely used against cancer; high concentrations of drug are 
required due to its low cellular uptake (173, 174). It has been found that MTX introduced 
40 
 
together with fluorescent probe around the CNTs sidewalls (175), can offer the possibility 
for improving bioavailability and, in the presence of a targeting unit, to address 
specifically cancer cells. Consequently MTX is rapidly internalized inside the cell by 
carbon nanotubes.  Preliminary results have shown that MTX conjugated to carbon 
nanotubes is as active as MTX alone in a cell culture (176). The stable amide bond between 
the MTX and the tubes could be the reason for lack of enhanced efficacy. Indeed, the 
drug is probably released too slowly from the tubes into the cytoplasm for an efficient 
interaction with its receptor. One solution to this problem could be to introduce a 
cleavage linker or a more enzymatically sensitive bond in the MTX conjugated CNTs, as 
demonstrated for conjugates based on dendrimers (177). 
 
2.2.3.3. Folic acid delivery by CNTs 
 
Folic acid conjugated CNTs has been found necessary to operate as receptor for targeting 
moiety during the path uptake of drug delivery. Passive targeting approaches are limited 
in their scope and thus, tremendous effort has been directed towards the development of 
active approaches for drug targeting. Active targeting employs specific modification of 
drug/drug-carrier nanosystems with “active” agents having selected affinity for 
recognizing and interacting with a specific cell, tissue or organ in the body (178).Direct 
coupling of drug to targeting ligand, restricts the coupling capacity to a few drug 
molecules. In contrast, coupling of drug carrier nanosystems to ligands allows import of 
thousands of drug molecules by means of one receptor targeted ligand.  
 
Drug targeting to specific cells has been explored utilizing the presence of various 
receptors, antigens/proteins on the plasma membrane of cells and also by virtue of the 
lipid components of the cell membranes. The presence of receptors on cell membranes 
potentiates active targeting by not only allowing specific interaction of drug carrier 
system with cells, but also facilitating its uptake via receptor mediated endocytosis. 
 
Folic acid, a vitamin essential for de novo nucleotide synthesis is taken up by cells via 
receptor mediated endocytosis using membrane associated folate receptors. Folate 
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receptors are expressed only on certain epithelial cells in humans, but are differently 
over-expressed in cells of cancers with epithelial origin. It has been primarily used for 
tumor specific drug delivery in many cancers including breast, ovary, brain and lung 
malignancies. Significant over-expression of folate receptors on a variety of tumor cells 
allows targeting moety. Folate has been conjugated to radiolabelled dendrimers and to 
liposomes to affect preferential uptake and accumulation of therapeutic agents in tumor 
cells. Induction of folate receptors with retinoid compounds followed by folate 
conjugated liposomes, has been used successfully for therapy of acute myelogenous 
leukemia. This treatment modality was also found to bypass the p-glycoprotein (Pgp) 
mediated drug efflux mechanisms. The application of folic acid to MTX conjugated CNT 
as targeting moiety can render more efficacious the translocation of MTX to the 
cancerous cells.  
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CHAPTER 3 
EXPERIMENTAL SECTION 
 
3.1.     General Procedures 
 
1H NMR spectra were obtained at 300MHZ and 400MHZ in DO2 solution. The chemical 
shifts, δ in ppm, were referenced against sodium 3-(trimethylsily)-2, 2, 3, 3-d4 propionate. 
The pH values of the sample in DO2 solution were adjusted to 10-11 by adding sodium 
hydroxide in order to eliminate potential protonation effect. Solid-state Infrared (IR) 
spectra were recorded on KBr pellets over the region of 4000-600cm-1. The attention was 
turned only on the significant bands. 
 
Dialysis was performed using cellulose membrane spectra (Spectrum Industries, Los 
Angeles, CA), with a molecular mass cut-off limit of 12000-14000. Distilled water was 
used for the dialysis phase. Freeze-drying of aqueous polymer and conjugate solutions 
were performed in a VIRTIS bench-Top 3 Freeze-drier operating at -30˚C and 10-15Pa. 
The freeze-dried polymers were routinely post-dried in a SARTORIUS Thermo Control 
Infrared drying apparatus and kept in desiccators. Samples for analysis were dried using 
the Abderhalden apparatus, and calcium chloride was done on a HITACHI 2000 
spectrometer, at a scan speed of 400nm/min; both analytical methods were performed in 
the school of chemistry of the University of Witwatersrand. Flash chromatography was 
performed using basic alumina as a solid support. The aprotic solvent, N,N-
dimethylformamide (DMF), was redistilled and kept over molecular sieves. Using the gel 
permeation chromatography (GPC) with 2.5X60cm column packed with Sepharose 6 gel 
by the principle of weight average molecular weight (Mw), the polymer-drug conjugates 
were separated from other products.  
 
The carbon nanotubes (CNTs) were synthesized by chemical catalytic vapour deposition 
(CCVD), and the following apparatus were used: vertical silica plug, reactor, furnace, 
temperature regulator, system of rotameters, pressure controllers, valves to control the 
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flow of gases into the reactor, condenser, two delivery cyclones. The transmission 
electronic microscope (TEM) was used to characterise CNTs samples.  
 
3.2     Reagents and Solvents 
 
The hydroxyamines and diamines were used as received (Adrich Chemie, Fluka AG). 
These included: D,L aspartic acid, phosphoric acid, 3-dimethylamino-1-propylamide 
(DMP), diethylenetriamine (DET), 2-2- (ethylenedioxy)-diethylamine (EDDA), 1,3 
diaminopropane (PDA), dicyclohexylcarbodiimide (DCC), 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium fluorophosphates (HBTU), triethylamine (TEA), ferrocene, 
folic acid, methotrexate, sodium hygroxide, chloridric acid, glacial acetic acid, 
ammonium hydroxide, sulphuric acid and nitric acid. 
Acetylene, hydrogen, nitrogen and argon were high purity and used as received (AFROX, 
South Africa). 
 
Distilled water was used for preparative work. The reaction solvent, N,N-
dimethylformamide (DMF), was distilled under reduced pressure, with a fore-runs of 
around 10% being discarded, and was dried over molecular sieves 4Ả. Tetramethylurea 
(TMU) was received as high purity (Fluka Chemie). All other solvents, Diethyl ether 
(Et2O), hexane, acetone and toluene, were laboratory grade, received from commercial 
sources. 
.   
3.3      Experimental Procedures   
 
3.3.1. Macromolecular carrier 
 
3.3.1.1. Preparation of poly-αß-DL-succinimide 
 
A mixture of D.L. aspartic acid (25g) and H3PO4 (12.5g) was homogenized in a 2L 
round- bottom flask. Then the flask was placed on an oil bath at 250˚C. During the 
polymerization, the expansion of the mixture was controlled by nitrogen. The reaction 
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was allowed to proceed at 250˚C until the end of expansion. Thereafter, the temperature 
was reduced to 190˚C for another 2 hours. This product was washed with water until the 
pH was around 6. The product was then left in an oven for 72 hours. The yield was 14.82 
g which was dissolved in 60 ml of DMF and stirred for overnight (O/N). The brownish 
solution obtained was stirred again for 1 hour in ice bath, and 1.73 g of DCC added while 
the solution was stirred for another 4 hours in ice bath. The solution was allowed to 
continue at room temperature (RT) for overnight (O/N). The solution was centrifuged off 
to give a clear solution which was precipitated with distilled water. The precipitate was 
filtered off and was kept in an oven for 48 hours to give a brittle solid which resulted to 
the yield of 12.75g. Several experiments were done that the values are shown in        
Table 4.1.       
 
3.3.1.2. Synthesis of homopolymers  
 
A.  PSI-DMP (X) EDDA (Y) 
* PSI-DMP (80) EDDA (20) 
To a solution of PSI (2.95g; 30mmol) in DMF (37ml) was added DMP (2.40g; 24mmol) 
in DMF (7.5ml). The solution was flushed with Nitrogen gas and stirred for 24 hours at 
room temperature (RT). With stirring, the resultant solution was added dropwise to 
EDDA (2.67 g; 18mmol) in DMF (8ml) cooled in an ice bath. The solution was flushed 
with Nitrogen gas and stirring continued for 20 hours in the ice bath and for another 5 
hours at room temperature. The solution was then concentrated on the roti-evaporator at 
60˚C to reduce the volume to half. Polymer was precipitated out with a mixture of diethyl 
ether-hexane (2:1). Precipitate was washed with hot toluene followed by hot acetone 
several times. The precipitate was dissolved in distilled water. The pH solution was 
adjusted to 7-8 and the solution was dialyzed using 12000 membranes for 96 hours. For 
the last 6 hours of dialyses, the pH of the solution was adjusted to pH 4 for 5 minutes 
then re-adjusted to 9 with aqueous ammonia to eliminate N protonation. The product was 
freeze-dried to obtain the homopolymers of 4.1g as yield. The same procedure was 
observed for the preparation of all PSI-DMP (X) EDDA (Y) where the quantity of 
reagent was changing with the variation of mol ratio (X/Y) as illustrated in the table 4.2. 
45 
 
B.  PSI-DMP(X) PDA (Y) 
* PSI-DMP (80) PDA (20) 
To a solution of PSI (2.95g; 30mmol) in DMF (37ml) was added DMP (2.40g; 24mmol) 
in DMF (7.5ml). The solution was flushed with Nitrogen gas and stirred for 24 hours at 
room temperature (RT). With stirring, the resultant solution was added dropwise to PDA 
(1.33g; 18mmol) in DMF (8ml) cooled in an ice bath. The solution was flushed with 
Nitrogen gas and stirring continued for 20 hours in the ice bath and for another 5 hours at 
room temperature. The solution was then concentrated on the roti-evaporator at 60˚C to 
reduce the volume to half. Polymer was precipitated out with a mixture of diethyl ether-
hexane (2:1). Precipitate was washed with hot toluene followed by hot acetone several 
times. The precipitate was dissolved in distilled water. The pH solution was adjusted to 7-
8 and the solution was dialyzed using 12000 membranes for 96 hours. For the last 6 hours 
of dialyses, the pH of the solution was adjusted to pH 4 for 5 minutes then re-adjusted to 
9 with aqueous ammonia to eliminate N protonation. The product was freeze-dried to 
obtain the homopolymers of 5.58g as yield. The same procedure was observed for the 
preparation of all PSI-DMP (X) PDA (Y) where the quantity of reagent was changing 
with the variation of mol ratio (X/Y) as illustrated in Table 4.2. 
 
3.3.2. Polymer-Folic acid conjugates 
 
The conjugation of folic acid to amine-functionalized polymeric carriers was achieved by 
using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium fluorophosphates (HBTU) 
coupling agent. In addition, the experiment details followed the standard procedure 
adopted for the preparation of all polymer-folic acid conjugates herein investigated.  
 
3.3.2.1. General procedure for Polyaspartamide-Folic acid conjugates  
 
A. PSI-DMP(X)-PDA(Y)-FA. 
 Polymer carrier PSI-DMP(X)-PDA(Y) was dissolved in DMF. Folic acid was dissolved 
in DMF at 50˚C which was added to the polymer solution and stirred. As stirring 
continued, HBTU predissolved in DMF, was then added dropwise over 20 minutes, 
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followed by the addition of triethylamine (TEA). The resulting yellow solution was 
saturated with N2 and stirred at ambient temperature for 2 hours. The polymeric conjugate 
was precipitated with Et2-O-hexane (2:1), isolated upon centrifugation and dissolved in 
H2O. The pH was adjusted to 10 using NaOH and followed by size exclusion 
chromatography on a 2.5×25cm column packed with Sephadex G25 and eluted with 
distilled H2O. The pH of the solution was readjusted to 7 (glacial acetic acid) to prevent 
hydrolysis, and the solution was dialyzed for 48 hours in Spectre/Por 6 tubing. The pH of 
the retentate was adjusted to 4 (HCl) to regenerate the unconjugated carboxyl group of 
FA from its salt. The aqueous solution was stirred at ambient temperature for 5 minutes, 
then the pH re-adjusted to 6 (NH4OH), and the dialysis in the same tubing was continued 
for another 8 hours with numerous changes of the aqueous outer phase for complete 
removal of inorganic salts. The retentate with pH ~8, was freeze-dried to afford z mg of 
yellow, water-soluble conjugate of Polyaspartamide-Folic acid.   
 
B.  PSI-DMP (95)-PDA (5)-FA  
 Quantity of compound and solvent needed. 
Polymer (200 mg, 0.1 mmol) in DMF (7mL). 
Folic acid (20.6 mg, 0.05 mmol) in DMF (3mL). 
HBTU (15.93 mg, 0.04 mmol) in DMF (1mL) 
TEA (10 mg, 0.1 mmol).  
The results for 1H NMR spectra (7) evaluation are reported in Table 4.9.  
 
3.3.2.2. Chemical kinetics of conjugates 
 
A. PSI-DMP (85)-PDA (15)-FA    
Quantity of compound and solvent needed. 
Polymer (200mg, 0.1 mmol) in DMF (7mL); Folic acid (50mg, 0.11 mmol) in DMF 
(6mL); HBTU (40mg, 0.10mmol) in DMF (3mL); TEA (18.5mg, 0.18 mmol). 
To establish the chemical kinetics, the reaction was stopped after an interval of time.  
The data after 1H NMR spectra evaluation for reaction kinetic are illustrated in Table 4.5. 
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B. PSI-DMP (80)-PDA (20)-FA  
Quantity of compound and solvent needed. 
Polymer (200mg, 0.1 mmol) in DMF (7mL) 
Folic acid (108mg, 0.22 mmol) in DMF (6mL) 
HBTU (86mg, 0.20 mmol) in DMF (3mL) 
TEA (25mg, 0.24 mmol) 
To establish the chemical kinetics, the reaction was stopped after an interval of time.  
The data after 1H NMR spectra evaluation for reaction kinetic are illustrated in Table 4.7. 
 
3.3.3. Carbon nanotubes (CNTs) carrier 
 
3.3.3.1 Preparation of CNTs 
 
A. Experimental Procedure 
a) Precautions taken during the experiment 
• Caution should be taken when working with the furnace since it operates under 
higher temperature viz. 850-115000C. 
• Always put on the dusk when handling nanotubes since they can easily be 
dispersed and can damage the eyes and lungs. 
• Always put on the lab coat and hand gloves for safety measures. 
• Exit door should always be opened in case of explosions within the system. 
• Fire arresters are installed on the hydrogen and acetylene flow lines. 
b) Production Procedures 
The furnace reactor and the furnace vessel are initially heated to the desired temperatures 
in the presence of nitrogen flow within pipelines. When the temperature is still rising, all 
the leaks are checked within the system and get rectified. The leaks are usually noticed by 
the presence of bubbles when spraying small amounts of gas leak detector at the pipe 
joints. Since nitrogen is flammable and dangerous at higher temperatures, it is only 
allowed to flow when the furnace temperature is still lower than 500oC. Above this 
temperature, nitrogen flow is stopped by closing the nitrogen gas cylinder (main valve), 
followed by the pressure gauge on the cylinder. Nitrogen is then allowed to drain from 
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the pipelines and when it is drained the valve on the nitrogen flow meter is closed. While 
nitrogen drains, argon is allowed to flow within the pipelines by opening the argon gas 
cylinder and controlling the flow using the valve on the flow meter. When the desired 
furnace and ferrocene vessel temperatures are attained, a specific mass of ferrocene in its 
powder form is added into the vessel (150oC) while slowly opening the valves for 
hydrogen at 900oC and acetylene at 1050oC to the desired specifications, thereby 
allowing the flow of these gases together with argon and the catalyst within the pipelines. 
The system is then given enough time until the reaction commences. The product formed 
remains in the reaction tube and is collected when cleaning the equipment. During 
production, the gas sample is collected from the pipeline exit of the gas mixture. The 
system is stopped and allowed to cool for about 2 hours when there is no production of 
nanotubes anymore in the system or when blockage is encountered within the system.      
In order to eliminate the amorphous carbon, treat with 30% HNO3 the products collected 
in the cyclones, and stir the solution for 2 hours at room temperature. Then filter the solid 
products and wash the solid products to achieve pH 7. Finally, dry the solid products at 
120oC in hot air for 24 hours, and analyze the purified products with TEM, TGA, EDX, 
and Raman spectroscopy. 
Guidelines used when stopping the system at the end of production  
* Switch off the power source for all the temperature devices 
* Close the main valves from cylinders for acetylene and hydrogen gas 
* Allow all the gases to drain from the pipelines 
* Finally close all the valves on the flow meters. 
 
B. TEM Procedures 
The Samples collected will be analyzed through the Transmission Electron Microscope 
(TEM) by checking for the presence of long carbon chains. 
1) Before operating TEM machines, mix each representative sample with methanol and 
small droplet of each sample was dropped on the carbon grid.  
2) Feed a carbon grid covered with the sample to the TEM for analysis. 
3) Search the good spot of high purity nanotubes, thus longer length, by using the knobs 
indicated on TEM machine as depicted below. 
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4) Vary the magnification using magnification knob so to achieve a clear picture. 
5) After photographing the desired picture, discharge the carbon grid from the machine 
and analyze the next sample by following the same procedure.  
6) Collect the micrographs as result.  
7) Scan and print to get microscopic images.  
The total yield of multiwalled carbon nanotubes (MWCNTs) prepared was 8.56g. After 
TEM analysis, the microscopic image was captured with magnification 100000. This has 
led to evaluate the outer diameter (do) of 20nm and the inner diameter (di) of 10nm 
(Figure 4.16). 
 
3.3.3.2. Functionalization of CNTs 
 
A  MWCNTs with sulphuric acid and nitric acid 
a) Procedures: 
Treatment 1: The pristine MWCNTs were treated with hydrochloric acid, to remove 
impurities. One gram of MWCNTs was placed in a 500ml round-bottom flask and 200ml 
of HCl (32%) was added. The mixture was stirred using magnetic stirrer for 2 hours, then 
diluted in water, filtered, washed with deionised water and then dried overnight in a 
vacuum at 40ºC.   
Treatment 2: 0.1g of the purified MWCNTs were dispersed in 200ml of acid (mixture of 
sulphuric acid 95% and nitric acid 55% (3:1)) in a 500ml round bottom flask equipped 
with a condenser. The dispersion was kept differently for:  
1) 4 hours working with 100ºC 
2) 24 hours working with 50ºC 
3)  96 hours working at room temperature 
After that, the resulting dispersion was diluted in water and filtered. Then the resulting 
solid was washed up to neutral pH and the sample was dried in a vacuum at 40ºC 
overnight. 
The modified CNTs material was quantitatively analyzed by titration to determine the 
COOH concentrations on the surface of treated CNTs. In a typical experiment, the 
carboxylated CNTs were added into a 25ml 0.04 M NaOH solution and stirred for 48h to 
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allow the solid CNT material to equilibrate with the NaOH solution. The mixture was 
titrated with a 0.04M HCl solution to determine the excess NaOH in the solution and the 
concentration of the carboxylates on CNTs. 
 
b) TEM analysis: 
1) f-CNTs: MWCNTs + H2SO4 + HNO3 at 100ºC: d0=20nm & di=12nm (Figure 4.17). 
2) f-CNTs: MWCNTs + H2SO4 + HNO3 at 50ºC do=30nm (Figure 4.18). 
3) f-CNTs: MWCNTs + H2SO4 + HNO3 at RT do=80nm & di=40nm (Figure 4.19). 
 
c) 1H NMR evaluation 
1)  1H NMR SPECTRA (26): f-CNTs: MWCNTs + H2SO4 + HNO3 at 100ºC  
A: -CH2-COOH & B: -CH2-OH. For 1Mol of COOH adsorbed on the surface of 
MWCNTs, correspond to 7.54 Moles of OH. 
2) 1H NMR SPECTRA (27): f-CNTs: MWCNTs+H2SO4+HNO3 at 50ºC 
A: -CH2-COOH & B: -CH2-OH. For 1 Mol of COOH adsorbed on the surface of 
MWCNTs, correspond to 2.27 Moles of OH. 
3) 1H NMR SPECTRA (28): f-CNTs: MWCNTs+H2SO4+HNO3 at RT 
A: -CH2-COOH & B: -CH2-OH. For 1Mol of COOH adsorbed on the surface of 
MWCNTs, correspond to 0.08 Mol of OH. 
 
d) The results obtained from the 1H NMR spectra (26, 27 and 28) were used to evaluate 
the mol ratio incorporation of COOH and OH on the surface of CNTs by using the 
titration formula Y= 1 - 0.04X with Y: mmol of COOH on the surface of CNTs and X the 
volume of HCl in ml. The table 4.10 shows the incorporation of COOH and OH at 
variable temperatures. 
    
 
B.  Aspartic acid  
a) Procedures:  
0.15g of MWCNTs were dispersed in a mixture of 3g of Aspartic acid and 15ml of DMF 
in a round-bottom flask of 250ml equipped with a condenser, and the reaction was 
51 
 
controlled to 220ºC for 6 hours. After filtration, the solid was washed with water until 
neutral pH. The yield was 183mg. 
Using titration formula Y= 1 - 0.04X with Y: mmol of COOH on the surface of CNTs 
and X the volume of HCl in ml, see section 4.3.2.1 (B. 4) for results. 
 
b) 1H NMR (29) Analysis with D2O +NaOH has shown CH2-COOH pick at the chemical 
shift (3-2.3) expected. 
 
c) TEM Analysis according to microscopic image obtained in Figure 4.24 has shown the 
nanotubes structure with d0 = 60nm. 
 
C. Poysuccinimide (PSI) 
a) Procedures 
PSI (1g) was dissolved in 15ml of DMF in a round-bottom flask of 250ml occupied with 
the condenser, and 150mg of CNTs were dispersed in the same flask where the reaction 
was controlled to 160ºC after 48 hours, the pH was kept to 7. The solid was collected 
after filtering, dried and then washed with DMF in low temperature using the ice bath to 
remove free PSI and with acetone to remove DMF. Solid was collected, dried and kept in 
desiccators. The yield was 216mg 
 
b) The 1H NMR spectra (30) analysis with D2O+NaOH has shown the expected picks 
(see Appendix) –CO-CH2 (3.030-2.650), CH-N (4.5-4.45), H aromatic (7.940)  
 
c) The TEM analysis  
 The micrograph image in figure 4.26 was evaluated: do = 60nm and di = 40nm. 
 
 
 
 
 
 
52 
 
3.3.4. Functionalized carbon nanotubes (f-CNTs)-folic acid conjugates  
 
3.3.4.1. f-CNTs (H2SO4+HNO3 at 100˚C) bound folic acid 
 
A. Procedures  
100mg of f-CNTs (prepared at 100˚C) representing 0.38 mmol COOH was dispersed in 
5ml of DMF, and 11.6mg (0.114 mmol) of 3-dimethylamino-1-propylamine (DMP) 
representing 30% of molecular rate, was dissolved in 4ml of DMF. After Nitrogen 
flashing, the dispersion and the solution were mixed together in a round bottom flask, 
stirred at 50˚C. While solution was still stirring, 75mg (0.32 mmol) of 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium fluorophosphates (HBTU was added, and 
the pH was controlled to 7 using the triethylamine (TEA) dropwise. After 24 hours of 
reaction, a solution of 141mg (0.32mmol) 20% excess of folic acid in 10ml of DMF was 
prepared for 1 hour and was added in the main solution. Stirring continued during 6 hours 
while the pH was kept to 7 with TEA. The solid was collected by filtration and washed 
several times with tetramethylurea (TMU) to remove the excess of folic acid and acetone 
to remove the TMU. The solid was dried and kept in the desiccators.  
The yield was 163mg. 
 
B. 1HNMR spectra (31) analysis shows the expected picks as evaluated in Table 4.11. 
 
C. TEM analysis according to the microscopic image was evaluated in Figure 4.28 to      
d0 = 50nm & di = 20nm as nanotubes structure size. 
  
3.3.4.2. f-CNTs (Aspartic acid)
 
bound folic acid (f-CNTs-DMP (40)-FA (60)) 
 
A. Procedures 
100mg of f-CNTs representing 40mg (0.88 mmol) of COOH was dispersed in 5ml of 
DMF, and 36mg (0.352 mmol) of 3-dimethylamino-1-propylamine (DMP) (40%) was 
dissolved in 4ml of DMF. After Nitrogen flashing, the dispersion and the solution were 
mixed together in a round-bottom flask, stirred at 50˚C. During stirring, 206mg (0.88 
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mmol) of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium fluorophosphates 
(HBTU) predissolved in 3ml DMF was added dropwise, and the pH was controlled at 7 
using the triethylamine (TEA). After 24 hours of reaction, a solution of 303mg (0.7mmol) 
of folic acid in 15ml of DMF was prepared for 1 hour and was added into the main 
solution. Stirring continued for 6 hours while the pH was kept at 7 with TEA. The solid 
was collected by filtration and washed several time with tetramethylurea (TMU) to 
remove the excess of folic acid and acetone to remove the TMU. The solid was dried and 
kept in the desiccators. 
The yield was 231mg. 
 
B.1H NMR (32) shows different expected picks: A, B, C, D, E, F, and G represented in 
the Table 4.12 
In order to evaluate the incorporation of folic acid, A pick has been taken as reference 
pick where nH expected was 4H, and the aromatic picks (E, F, G) was calculated to 
15.2H over 15H expected. This resulted to the folic acid incorporation of 101.3%. 
 
C. TEM Analysis according to microscopic image (Figure 4 29) has shown the 
nanotubes structure with d0 = 170nm. 
  
3.3.4.3. f-CNTs (PSI)
 
bound folic acid (f-CNTs-DMP (40)-PDA (60)-FA) 
 
A.   Procedures 
The solid f-CNTs (200mg) were dispersed in 10ml of DMF in a round flask of 250ml. 
23mg of DMP dissolved in 5ml of DMF, was added to solution. Solution was stirred for 
24 hours at room temperature. Then 50mg PDA dissolved in 5ml of DMF was added 
dropwise in an ice bath for 24 hours. Filtered solid was collected and washed several 
times with hot toluene and acetone and filtered again, dried and dispersed in DMF. Folic 
acid 230mg dissolved in DMF was added to the solution. HBTU 134mg pre-dissolved in 
DMF was added dropwise while the solution was allowed to stay at pH of 7 using TEA. 
After 2 hours, the solid was collected, filtered and washed using TMU with the acetone. 
The yield: 356mg. 
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B. The 1H NM spectra (33) analysis with D2O+NaOH has shown the expected picks 
(see Appendix)  with A: -CH2-CH2-CH2, B: CH2-N(CH2)3, C: CH2-COONH, D: 
COCH2NH, (E, F, G, H): H aromatic.  
 
C. The TEM analysis was done (Figure 4.30)   
The micrograph image in the Figure 4.30 was evaluated: do = 80nm and di = 40nm. 
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CHAPTER 4 
 
 
RESULTS AND DISCUSSION 
 
4.1. Polymeric Drug Carriers 
 
With the objective to accommodate the anticancer drug models only to the cancerous 
cells, an attempt was made to afford tailor-made drug carriers through the design and 
derivation of several synthetic polymeric structures. This possibly will prevent the 
destruction of normal cells and provide an adequate liberation of the drug without any 
deposition to the kidney which could raise certain side effects due to the toxicity of the 
agents. Note that the synthesis by bioreversible conjugation of selected anticancer drug 
models with water-soluble macromolecule carriers, and the biological activity evaluation 
of the resulting conjugates, is two objectives to be fulfilled in respect of necessary 
prerequisites for any macromolecule intended to serve in the biomedical field. The 
polymeric carriers used for the anchoring of the selected drug models fell into the wide 
aliphatic polyamide type (schematized below) with subunits randomly distributed along 
the chain.  
 
Scheme 4.1: Structure of polyamide-type carrier 
 
In this scheme, S represents an extra-or intra-chain hydrosolubilizing group required to 
impart water–solubility to the ultimate polymer-drug conjugate. S is a tertiary amine, 
hydroxyl or methoxy functionality. F stands for extra-or intra-chain functional group 
capable of reversible-drug anchoring. In this study, to provide access to the polymer-drug 
binding via amide bond formation, the choice was made on a primary amino group. The 
most important point is that the amide bond performs the ability to develop biofission, 
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which results in the enzymatic activity in the intracellular lysosomal compartment, and 
causes the drug release from the cytoplasmic space. The incorporation of additional 
subunits of the preset structures, if necessary, will be granted to afford tailor-made 
polymers that are equipped with all required functions. This allows efficacious 
administration and enhanced pharmacokinetics of the anticancer drug. 
 
The drug used being hydrophobic, the polymeric carriers were designed to provide a 
balance between the load of these inherently hydrophobic drugs and the solubilizing 
moieties on the polymer, because hydrophobic polymer-drug conjugates are required at 
varying concentrations. The side chains were tertiary amine. The choice of the structures 
was based on the following considerations: 
(a) The weight-average molecular weight, generally in the range of 20 000-30 000, is 
sufficiently low to suppress (chain length-dependent) inherent polymer toxicity, 
but still high enough to retard renal clearance. The conjugates, therefore, enter 
cells easily owing to the enhanced permeability retention (EPR) effect.  
(b) The intrachain amide groups assist in gradual backbone cleavage for ease of 
catabolic elimination of the polymer in the “spent” state. The stereoisomeric 
“scrambling” of any peptide units in the backbone chain impedes unduly rapid α-
peptidase-mediated “unzipping”, ensuring this fragmentation to be an 
appropriately retarded process. 
(c) Property selected polyamides are essentially non-toxic, and immunogenicity of 
these synthetic polymers is expected to be appreciably lower in comparison with 
that commonly occurring with high-molecular-weight proteinaceous biopolymers. 
(d) The S-modified subunits can easily be introduced as majority components (x>y), 
thus ensuring effective insulation of the F-modified subunits from each other. 
This will reduce the risk of intramolecular interaction of adjacent conjugated drug 
species. 
(e) Tertiary amine functions can be introduced as side groups to provide the special 
functions of adsorptive pinocytotic cell entry and target cell affinity.  
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(f) While inherently water-soluble, with S comprising selected amine or hydroxyl 
functions, the polyamides can be made to acquire additional solubility in 
methanolic medium. This can be achieved by incorporation of poly(ethylene 
oxide) (PEO) side chains as additional solubilizing groups. This added solubility 
feature will be advantageous in follow-up reactions in alcoholic media. 
(g) When synthesized from amino acid monomers, the polyamide carrier will provide 
vitally required nutrients for the rapidly growing cell tissue, and hence may be 
preferentially taken up by the cancerous cell. 
      The polyamide conforming to the basic carrier model (Scheme 2.2), namely 
Polyaspartamide (PAsA) was used for drug conjugation by amide bond formation 
between the carriers and the carboxylic acid-functionalized drugs. The primary amine 
functional groups of these polymers were introduced as terminals in component F. The 
subunits incorporating this binding site form 5 to 20 mol-% of the tert-amine for 80mol-
% of S-labeled subunits of the tert-amine for hydrosolubilization. With recognition of the 
incorporation of drug from F-labeled subunits of the primary-amine, the carrier 
containing larger mole percentages of F-labeled subunits will be needed for utilization of 
an unduly large excess of drug to provide complete drug incorporation. In addition, the 
coupling products so obtained had displayed a predisposition for branching and 
crosslinking with concurrently decreasing solubility once they had been isolated in the 
solid state. The purification of polymeric carriers was completed by dialysis to remove 
constituents with molecular weight substantially below 12 000. 
       4.1.1. Polyaspartamide carriers (PAsA) 
The Polyaspartamides containing the backbone bound to the solubilizing group at one 
side and anchoring drug at the other side were prepared from polysuccinimide. 
4.1.1.1. Synthesis of polysuccinimide (PSI) 
Two different methods for the synthesis of polysuccinimide (PSI) have been set in the 
literature, including the polymerization of N-carboxyanhydride of α-amino acid in 
general (NCA method) (179) and the thermal phosphoric acid-catalyzed polycondensation 
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of aspartic acid (Neri method) (180). The NCA method was found to be disadvantageous 
both in cost and production as the pendent reactive groups carried by the amino acid had 
to be protected before polymerization, and disclosed under harsh considerations to give 
poly (amino acid). Specially to organize the large amounts of phosgene, diphosgene or 
triphosgene, a reagent widely used for the synthesis of N-carboxyanhydride, raised 
complex safety problems in a large-scale plant. On the contrary, the Neri method is 
reported to deliver high molecular weight PSI in one step (181). Because of this advantage, 
this approach was adopted for the synthesis of poly-DL-succinimide (PSI) from DL-
aspartic acid as shown in Scheme 4.2. The crude polymer was treated with 
dicyclohexylcarbodiimide (DCC) coupling agent for further chain extension purposes. A 
representative polymer had a relative viscosity of 36 mL g-1 in DMF at 30ºC, which 
corresponds to a weight-average molecular weight of 32000.  
 
Scheme 4.2: Synthesis of polysuccinimide (PSI) 
 
A. Results of Synthesis of polysuccinimide (PSI) 
The 1H NMR spectrum of PSI in DMSO-d6 showed a large resonance at 5.2 ppm 
corresponding to the methine proton (NCO-CH). The methylene protons (CH2CH) are 
seen as two peaks of the roughly equal intensity at 3.3 and 2.6 ppm.  
In addition, several experiments were performed to prepare the poly-DL-succinimide 
(PSI-DCC) as shown in Table 4.1. 
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Table 4.1: Quantitative values of PSI synthesis 
 
EXP. NO 
Aspartic. 
Acid (g) 
 
Phosphoric 
Acid (g) 
PSI*a 
Yield    
g (%) 
DMF 
(ml) 
DCC 
(g) 
 
PSI 
Yield         
g (%) 
 
1 25 12.5 14.82 (59.28) 60 1.73 
 
12.75 
(86.03) 
 
2 75 32.5 45.51 (60.68) 130 5.31 
 
41.23 
(90.59) 
 
3 80 40 52.18 (65.23) 64 6.10 
 
43.98 
(84.28) 
 
4 100 50 58.5 (58.50) 150 6.83 
 
49.91 
(85.32) 
 
5 50 25 31.43 (62.86) 126 3.67 
 
27.95 
(88.93) 
 
6 80 40 50.07 (62.26) 150. 5.84 
 
41.64    
(83.17) 
 
7 80 40 53.08 (66.35) 150 6.20 
 
47.16 
(88.84) 
 
8 70 35 41.20 (58.86) 150 4.78 
 
36.70 
(89.08) 
 
 
                                                 
a
 PSI*: Before treatment with DCC coupling agent. 
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B. Discussion of Results of Synthesis of polysuccinimide (PSI) 
The yield for the synthesis of polysuccinimide was varying in the range of (58-67%) 
before treatment with DCC coupling agent and (83-91%) after treatment with DCC 
(Table 4.1). This shows that the loss was more performed in the first stage of treatment 
(PSI*) than in the second stage (PSI after DCC treatment). After investigation, the 
following options can be the cause of dropping of yield in the first stage of treatment: 
1. A big quantity of free aspartic acid did not react during the polycondensation and was 
liberated when the product was washed to adjust the pH to 7.  
2. During the operation of adjusting the pH to 7 by washing the product several times 
with the distilled water, the loss of polymer is inevitable. This, because some product can 
be hydraulically involved by the water and other being fractionated by hydrolysis. 
The yield of PSI was in the range of (83-91%) after treatment with DCC coupling agent 
while the expected yield should be 100%.                                                                        
4.1.1.2. Preparation of homopoly (α, β-DL-aspartamides)  
Referring to Scheme 4.2 which reveals the structure of the X repeat units giving poly-
DL-succinimide, the opening of the ring will be required to provide a long chain with 
subunits partly displaying in one hand the solubility, on the other hand the anchoring 
drug. Note that polyaspartamides are readily prepared from poly DL-succinimide by an 
aminolytic ring-opening process in anhydrous, dipolar aprotic medium, such as N,N 
dimethylformamide (DMF) at 0-25⁰C. The product is racemic and possesses both α-and 
β-peptidic repeat units. Scheme 4.3 shows the preparation of homopoly(α, β-DL-
aspartamides) by the poly-DL-succinimide aminolytic ring-opening process using one 
type of amine reactant.   
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Scheme 4.3: Preparation of homopoly(α, β-DL-aspartamides) 
While D-type polymers are resistant to enzymatic cleavage, L-type polymers are more 
prone to rapid enzymatic degradation. Therefore, a backbone structure of the DL-racemic 
mixture will ensure retarded enzymatic cleavage and ultimate backbone degradation as a 
result of hydrolytic cleavage. 
4.1.1.3 Preparation of copolyaspartamides (PAsA) 
Respecting a stepwise process which involves the utilization of two or more different 
amine reactants in a given stoichiometric feed ratio, aminolytic ring-opening can lead to 
the generation of copolyaspartamides. By using sequentially H2N-R and H2N-R’-NH2 to 
form polyaspartamides, in which subunits featured R and R’-NH2 in predetermined ratios 
along the chain. Varying R and R’, a series of random copolyaspartamides were prepared 
as drug carriers.  
When working with 3-(N, N-dimethylamino)propylamine (DMP) which R: -(CH2)3-N-
(CH3)2, and 1,3-propylenediamine (PDA) which R’: -(CH2)3- reaction parameters should 
be considered to lead the reaction to the expected products. DMP, being tertiary amine 
group, acts as both hydrosolubilizing and cell-selecting group. Many considerations 
supporting the choice of this group from all those investigated in this laboratory (182).   
Note that the DMP is a strong base which means that the protonation will be evident even 
under weak basic conditions. The protonation, carrying more cationic, will cause the 
amino group to be positively charged, this will preferentially approach surfaces of certain 
types of cancer cells that are negatively charged. This will promote the adsorptive 
pinocytotic cellular uptake of the macromolecules as reported by Shen (183).  
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The challenge was to solve the problem of competition between NH2-R (DMP), and NH2-
R’-NH2 (PDA) which could take place during the reaction. The first reactant to be used 
was found to be less reactive than the second, and was used as major reactant (X > Y) in 
the two-step preparative process of these polymers. In accordance with chemical 
reactivity, NH2-R’-NH2 (PDA) due to both two extremes -NH2, is more reactive than 
NH2-R (DMP) presenting –NH2 in one extreme only. Then, the first step is the reaction in 
anhydrous conditions between a given amount of polysuccinimide and its corresponding 
R-NH2 counterpart. This reaction, based on the desired X/Y feed ratio, is performed at 
room temperature. With respect to achieve the desired percentage incorporation with 
complete ring opening and substitution of the remaining succinimide units of the 
substrate polymer without causing crosslinking through involvement of the terminal 
amino group, the following conditions were respected during the reaction: 
1. Considering that –NH-R’-NH2 (after reaction) is less reactive than NH2-R’-NH2, 
excess of PDA was needed to prevent –NH-R’-NH2 to continue to react in another 
step. For the activity of –NH-R’-NH2 in reaction is conditioned by the absence of 
NH2-R’-NH2 in the same reaction. 
2. The diminution of the temperature to minimize the activity of PDA, thus the use 
of an ice bath was required to bring the temperature down. 
3. The polymer solution was released dropwise in the PDA solution.  
4. In addition, DMP and PDA steps were performed under strictly anhydrous 
conditions in order to avoid unwanted hydrolytic ring opening, resulting in the 
generation of free carboxylic side group.  
The polymeric products were isolated as completely water-soluble solids by a series of 
operations which involved precipitation with adequate non-solvents, aqueous dialysis (in 
tubing with 12000 molecular weight cut-off-limit), and freeze-drying. As the 
consequence of the crude fractionation achieved by this dialysis step, yields did not 
exceed 85%, generally ranging from 85% to 70%. The inherent viscosities (ŋinh) ranged 
from 11 to 22mLg-1. The 1HNMR spectra of polymers (P1) measured in D2O, and 
recorded at pH 10-11 for elimination of protonation effects, showed characteristic band 
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groups, some containing overlapping signals. Thus, the CH (methine) signal of aspartic 
appeared in the region of 4.75-4.5 ppm; CH2-O (methylene) and CH-OH (methine) 
signals were grouped in the region of 3.7-3.6 ppm. The methylene protons of CONH-CH2 
were found in the region of 3.5-3.0 ppm. Proton signals of CO-CH2, CH2-N(CH3)2, CH2-
NH, and CH2-NH2 were found in the region of 2.9-2.0 ppm. Methylene protons of 
CH2CH2CH2 were found in the 1.8-1.5 ppm region.                                                            
A. PSI-DMP(X)-EDDA(Y) 
a) PSI-DMP (90)-EDDA (10)                                                                                         
Using 2.95g (30mmol) of PSI as reference, 2.76g (27mmol) of DMP and 1.33g (9mmol) 
of EDDA were required to prepare the polymeric carrier PSI-DMP (90)-EDDA (10). The 
results are presented in Tables 4.2, 4.3 and 4.4.                                                                      
The evaluation of 1H NMR Spectra 1 (Appendix) calculated in Table 4.4 gave 98% 
incorporation of EDDA in the Homopolymer. 
b) PSI-DMP (80)-EDDA (20) 
 Using 2.95g (30mmol) of PSI as reference, 2.45g (24mmol) of DMP and 2.67g 
(18mmol) of EDDA were required to prepare the polymeric carrier PSI-DMP (80)-
EDDA (20).  The results are presented in Tables 4.2, 4.3 and 4.4. 
The evaluation of 1H NMR Spectra 2 (Appendix) calculated in Table 4.4 gave 95% 
incorporation of EDDA in the Homopolymer. 
 
B. PSI-DMP (X) PDA (Y) 
a) PSI-DMP (95)-PDA (5)                                                                                          
Using 2.95g (30mmol) of PSI as reference, 2.91g (28.5mmol) of DMP and                
0.33g (4.5mmol) of PDA were required to prepare the polymeric carrier                                
PSI-DMP (95)-PDA (5). The results are presented in Tables 4.2, 4.3 and 4.4.  
The evaluation of 1H NMR Spectra 3 (Appendix) calculated in Table 4.4 gave 94% 
incorporation of PDA in the Homopolymer. 
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b) PSI-DMP (90)-PDA (10) 
Using 2.95g (30mmol) of PSI as reference, 2.76g (27mmol) of DMP and 0.67g (9mmol) 
of PDA were required to prepare the polymeric carrier PSI-DMP (90)-PDA (10).         
The results are presented in Tables 4.2, 4.3 and 4.4.  
The evaluation 1H NMR Spectra 4 (Appendix) calculated in Table 4.4 gave 98% 
incorporation of PDA in the Homopolymer. 
 
c) PSI-DMP (85)-PDA (15)                                                                                           
Using 2.95g (30mmol) of PSI as reference, 2.60g (25.5mmol) of DMP and 0.63g 
(8.5mmol) of PDA were required to prepare the polymeric carrier PSI-DMP (85)-PDA 
(15).  The results are presented in Tables 4.2, 4.3 and 4.4.  
The evaluation of 1H NMR Spectra 5 (Appendix) calculated in the Table 4.4 gave 102% 
incorporation of PDA in the Homopolymer.   
 
d) PSI-DMP (80)-PDA (20)                                                                                                   
Using 2.95g (30mmol) of PSI as reference, 2.45g (24mmol) of DMP and 1.33 (18mmol) 
of PDA were required to prepare the polymeric carrier PSI-DMP (80)-PDA (20). The 
results are presented in Tables 4.2, 4.3,4.4.                                                                       
The evaluation of 1HNMR SPECTRA 6 (Appendix) calculated in the Table 4.4 gave 
101% incorporation of PDA in the Homopolymer. 
C. Results  of Preparation of copolyaspartamides (PAsA)                                                                                                             
The results related to the preparation of different copolyaspartamides achieved by 
varying the solubilising groups and the mol ratio X/Y, are presented in Tables 4.2, 4.3 
and 4.4. The corresponding inherent viscosity (ηinh) versus mol ratio (X/Y) plot is shown 
in Figure 4.1.  
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Table 4.2: Quantitative values of PSI-DMP (X) –PDA (Y) /EDDA (Y)  synthesis 
 
 
Chemical compound 
 
X Y X/Y 
 
Mass (g)  
(mol) 
Yield 
(g) 
PSI DMP 
 
PDA   
 
  EDDA 
 
 
 
PSI-DMP (X) -PDA (Y) 
80 20 4/1 2.95 (30) 
2.40 
(24) 
1.33 
(18) 
 
5.58 
 
85 15 17/3 2.95 (30) 
2.55 
(25.5) 
0.63 
(13.5) 
 
4.02 
 
90 10 9/1 2.95 (30) 
2.70 
(27) 
0.67 
(9) 
 
3.86 
 
95 5 19/1 2.95 (30) 
2.91 
(28.5) 
0.33 
(4.5) 
 
3.86 
 
 
PSI-DMP (X)-EDDA (Y) 80 20 4/1 
2.95 
(30) 
2.40 
(24) 
2.67 
(18) 
 
4.1 
 
90 10 9/1 2.95 (30) 
2.70 
(27) 
1.33 
(9) 
 
3.87 
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Table 4.3: Inherent Viscosity, base molecular weight and yield for PSI-DMP (X)-
PDA / EDDA(Y). 
 
Chemical compound 
 
X Y X/Yb BMwc ηinh
d
 
(mLg-1) 
 
Yield 
(g) 
 
PSI-DMP (X)- PDA (Y) 
80 
85 
90 
95 
20 
15 
10 
5 
4/1 
17/3 
10/1 
19/1 
968.21 
3900.89 
1964.47 
3956.99 
18.38 
16.62 
12.23 
10.13 
 
3.39  
3.42 
3.86 
3.68 
 
PSI-DMP (X)-EDDA (Y) 
80 
90 
20 
10 
4/1 
9/1 
1042.29 
2038.55 
18.7 
11.31 
 
4.13 
4.52 
 
 
 
 
Figure 4.1: Inherent viscosity of PSI-DMP (X)-PDA (Y) versus Mol Ratio (X/Y).
                                                 
b
 X/Y: Mole ratio of hydrosolubilizing to drug-anchoring groups 
c
 BMw: Base molecular weight of simple recur 
d
 ηinh: Inherent viscosity 
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Table 4.4: 1H NMR spectra analysis of PSI-DMP (X)-PDA /EDDA (Y) 
 
 
 
Chemical 
Compound 
 
 
 
X 
 
 
Y 
 
 
X/Y 
 
HNMR 
spectra 
Chemical shift (δ/ppm) 
Calculated (expected) 
 
% 
PDA 
        % 
   EDDA 
 
 
 
Yield 
(g) CH Asp 
4.75-4.5 
CONH-CH2 
3.7-3.5 
-CO-CH2, 
CH2NH2 
3.5-3.0 
CO-CH2, 
CH2N(CH3)2, 
2.8-2.0 
CH2CH2CH2 
1.8-1.5 
 
 
 
PSI-
DMP(X)-
PDA (Y) 
80 
 
85 
 
90 
 
95 
20 
 
15 
 
10 
 
5 
4/1 
 
19/1 
 
9/1 
 
19/1 
6 
 
5 
 
4 
 
3 
5  (5) 
 
20  (20) 
 
10.2(10) 
 
20.4(20) 
10.1 (10) 
 
40.8  (40) 
 
20  (20) 
 
40.8  (40) 
11.1 (12) 
 
45.6  (46) 
 
23.2  (22) 
 
44.4 (42) 
33.3 (32) 
 
140.8 (136) 
 
70.4 (72) 
 
144 (154) 
10 (10) 
 
20 (20) 
 
20 (20) 
 
40 (40) 
104 
 
104 
 
98 
 
94 
3.39 
 
 
3.42 
 
 
3.86 
 
 
3.68 
PSI-
DMP(X)-
EDDA(Y) 
80 
 
90 
20 
 
10 
4/1 
 
9/1 
2 
 
1 
5 (5) 
 
10.3(10) 
7.3 (8) 
 
9 (8) 
10.3 (10) 
 
20.7 (21) 
41.7 (44) 
 
92 (94) 
8 (8) 
 
18 (18) 
95 
 
98 
4.52 
 
 
4.13 
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D. Discussion of Results of Preparation of copolyaspartamides (PAsA) 
 The minimum molecular weight of carriers was equal or above 12000 due to the 
application of cellulose tubing with weight-average molecular weight cut-off limits of 
12000. Since the weight-average molecular weight is one of biomedical requirements to 
determine the quality of the polymeric carrier, with the estimated minimum value of 
12000, though this value is not comprised in 20000-30000 range as stipulated in section 
2.1, it is possible to have most of the average molecular weight in the range 
aforementioned; this should be sufficiently low to suppress inherent polymer toxicity, 
unless the maximum molecular weight gives acceptable range. However, it will be high 
enough to retard renal clearance. 
 
The inherent viscosity revealed large differences in the stiffness of these 
copolyapastamides. The relation between inherent viscosity and the mole ratio of 
hydrosolubilizing to a drug-anchoring group as data in Table 4.3, showed in figure 4.1 
the decreasing of ηinh when the mol ratio (X/Y) increased. The inherent viscosity (ηinh) of 
copolyaspartamide as water soluble found in the range of 10 to 19mL g-1(Table 4.3) was 
less than the inherent viscosity (36mL g-1) of the polysuccinimide which is water 
insoluble (Section 4.1.1.1).
 
This shows how much the presence of solubilizing group as 
one of two subunits in the backbone displayed on the inherent viscosity. Since the 
inherent viscosity of the polysuccinimide without subunits is higher than the one for 
water soluble polymeric carrier, this confirms that the increasing of the quantity of 
solubilizing in the polymeric carrier relative to mol ratio X/Y (Fig. 4.1), involves the 
decreasing of inherent viscosity. When the quantity of amine used to solubilize the 
polymer decreases, the solubility of the carrier can be affected. Thus the solubility of 
macromolelar carriers is linked to the mol ratio which conditions the viscosity as shown 
in Figure 4.1.  
 
4.2. Polymer Drug Conjugation 
 
Varying the type of Polyaspartamide carrier, many polymer drug conjugations were 
prepared. The most important in this research is to prove the existence of the covalent 
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reversible attachment of the carrier through amide bond formation with the drug. Note 
that methotrexate and folic acid with both two carboxyl groups from their structures can 
be attached to the polymeric carrier through the amine group of the anchoring drug unit 
to form an amide group able to develop biofission. The investigation of folic acid will 
lead to the same conclusion when investigating methotrexate as agent. The rate 
incorporation of drug in the polymeric carrier calculated from 1H NMR integration, even 
in an acceptable range, could not confirm at all the covalent reversible attachment of the 
carrier with the drug. Nevertheless the chemical kinetics investigation through the change 
of fraction incorporation of the drug with the reaction time can assert the reversible 
attachment when the purification methods such as centrifugation, chromatography and 
dialysis are reliable. 
 
4.2.1. Polymer-folic acid conjugates 
 
The coupling was prepared in anhydrous medium (DMF) in the presence of HBTU 
coupling agent. HBTU was added to activate the reaction between the amine group of 
carrier and the carboxylic acid group of folic acid. The presence of bi-functionally active 
drug molecule can cause gradual crosslinking of ultimate conjugate especially when the 
coupling agent (HBTU) is used in higher mol ratio. There the use of HBTU in solution 
was done dropwise with an acceptable rate. To maintain the reaction pH between 6 and 7, 
an organic base triethylamine (TEA) was added dropwise to the solution. 
 
4.2.1.1. Results of Polymer-folic acid conjugates 
 
In order to achieve the chemical kinetics investigation, all reactions performed with mol 
ratio 17/3 and 4/1 for PSI-DMP (X)-PDA (Y)-FA were running in the same condition 
while the time was varying in the range of 10 to 130 minutes. Different data of fraction of 
incorporation of folic acid in the polymeric carrier were calculated through the evaluation 
of different 1H NMR Spectra integration from 1H NMR Spectra 8 to 25 as shown in the 
appendix. Both the fraction of incorporation of folic acid and the coupling yield in terms 
of reaction time have made possible through the base molecular weight (BMw) the 
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calculation of fractions of the retained polymer, removed polymer and folic acid in the 
coupling as shown in Tables 4.5, 4.6, 4.7 and 4.8. From these Tables, the different graphs 
were plotted in terms of the reaction time leading to the following figures: 
• Figure 4.2 and 4.9 related to fraction incorporation of folic acid versus the 
reaction time in the polymeric carrier (PSI-DMP (X)-PDA (Y)) for mol ratio 
(X/Y) 17/3 and 4/1 respectively. 
• Figure 4.3 and 4.10 related to the fraction of coupling yield of PSI-DMP (X)-PDA 
(Y)-FA with mol ratio (X/Y) 17/3 and 4/1 respectively, versus the reaction time. 
• Figure 4.4 and 4.11 related to the fraction of retained polymer with mol ratio 
(X/Y) 17/3 and 4/1 respectively, versus the time of reaction. 
•  Figure 4.5 and 4.12 related to the fraction of removed polymer with mol ratio 
(X/Y) 17/3 and 4/1 respectively, versus the time of reaction. 
• Figure 4.6 and 4.13 related to the fraction of folic acid in the coupling with mol 
ratio (X/Y) 17/3 and 4/1 respectively, versus the time of reaction. 
• Figure 4.7 and 4.14 related to the combining of all fractions versus the time with 
mol ratio (X/Y) 17/3 and 4/1 respectively, versus the time of reaction. 
• Figure 4.8 and 4.15 related to the inherent viscosity of PSI-DMP (X)-PDA (Y)-
FA with mol ratio (X/Y) 17/3 and 4/1 respectively, versus the reaction time. 
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Table 4.5: Incorporation FA data in terms of time for PSI-DMP (85)-PDA (15)-FA 
conjugate reaction. 
 
 
Reaction 
time 
(minutes) 
 
1HNMR 
SPECTRA 
(X) 
Chemical shift δ/ppm 
nH counted  
(nH expected) 
 
% FA 
incorporation 
8.7-6.75 1.7-1.6 
 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
120 
130 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
1.2 (15) 
3.2 (15) 
4 (15) 
4.4 (15) 
4.8 (15) 
5.2 (15) 
7.2 (15) 
8 (15) 
9.2 (15) 
12.4 (15) 
12.8 (15) 
13.6 (15) 
14.4 (15) 
40 (40) 
40 (40) 
40 (40) 
40 (40) 
40 (40) 
40 (40) 
40 (40) 
40 (40) 
40 (40) 
40 (40) 
40 (40) 
40 (40) 
40 (40) 
8 
21.3 
26.7 
29.3 
32 
34.7 
48 
53.3 
61.3 
82.7 
85.3 
90.6 
96 
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Table 4.6: Coupling Yield, FA incorporation and viscosity data in terms of time for 
PSI-DMP (85)-PDA (15)-FA conjugates reaction. 
 
Reaction 
time 
(minutes) 
% FA 
incorpor. 
(1HNMR) 
Yield 
Coupling 
 
Carrier in 
coupling 
Removed 
carrier 
FA in 
coupling 
ηinh 
(mLg-1) 
  mg % mg % mg % mg 
 
% 
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
120 
130 
0 
8 
21.3 
26.7 
29.3 
32 
34.7 
48 
53.3 
61.3 
82.7 
85.3 
90.6 
96 
200 
203 
204 
206 
207 
209 
209 
215 
219 
223 
225 
225 
223 
220 
75.44 
76.57 
76.98 
77.70 
78.08 
78.83 
78.83 
81.10. 
82.60 
82.60 
84.87 
84.87 
84.11 
83.98 
200 
198 
190 
189 
188 
188 
187 
185 
185 
184 
176 
174 
170. 
166 
100 
99 
95 
94.5 
94 
94 
93.5 
92.5 
92.5 
92 
88 
87 
85 
83 
 
0 
2 
10 
11 
12 
12 
13 
15 
15 
16 
24 
26 
30 
34 
0 
1 
5 
5.5 
6 
6 
6.5 
7.5 
7.5 
8 
12 
13 
15 
17 
0 
5.4 
13.8 
17.1 
18.7 
20.5 
22.1 
30.2 
33.5 
38.3 
49.5 
50.5 
52.4 
54.1 
0 
2.7 
6.8 
8.3 
9 
9.8 
10.6 
14 
15.3 
17.2 
22 
22.4 
23.5 
24.6 
16.62 
17.02 
17.95 
18.83 
18.34 
19.06 
19.27 
19.58 
19.93 
20.49 
20.65 
21.58 
21.78 
22.07 
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Table 4.7: Incorporation FA data in terms of time for PSI-DMP (80)-PDA (20)-FA 
conjugates reaction. 
 
Reaction 
time 
(minutes) 
1HNMR 
SPECTRA 
(X) 
Chemical shift δ/ppm 
nH counted  
(nH expected) 
 
8.7-6.75 1.7-1.6 
 
 
10 
25 
50 
60 
120 
 
21 
22 
23 
24 
25 
 
0.6 (5) 
1.2 (5) 
2.4 (5) 
2.7 (5) 
5    (5) 
 
10 (10) 
10 (10) 
10 (10) 
10 (10) 
10 (10) 
 
 
 
Table 4.8: Coupling Yield, FA incorporation and viscosity data with the reaction 
time. 
 
Reaction 
time 
(minutes) 
% FA 
incorpor. 
(1H NMR) 
Yield 
Coupling 
 
Carrier in 
coupling 
Removed 
carrier 
FA in 
coupling 
ηinh 
(mLg-1)
 
mg % mg % mg % mg % 
 
0 
10 
25 
50 
60 
120 
 
0 
12 
24 
48 
54 
100 
 
 
200 
205 
215 
226 
231 
238 
 
69.6 
71.3 
74.8 
78.6 
80 
82.8 
 
200 
194 
194 
185 
185 
163 
 
100 
97 
97 
92.5 
92.5 
81.5 
 
0 
6 
6 
15 
15 
37 
 
0 
3 
3 
7.5 
7.5 
18.5 
 
0 
10.6 
21.2 
40.6 
45.6 
74.5 
 
0 
5.2 
9.9 
18 
19.8 
31.3 
 
18.38 
18.86 
19.47 
20.08 
20.74 
23.02 
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4.2.1.2. Discussion of Results of Polymer-folic acid conjugates  
 
In a chemical reaction, the concentration of reactants decreases with reaction time, while 
the concentration of products increases when the reaction is irreversible. Figure 4.2 
shows that the fraction of incorporation of folic acid in the polymer was increasing with 
reaction time and the rate of the reaction was also time dependent. Thus, working with 
the minutes as time, the rate with incorporation range of 21.3-34.7% within the time 
range of 20-60 minutes is 0.335% min-1. The approximated rate of 0.443% min-1was 
found with FA incorporation range of 82.7-96% within the time range 100-130 minutes. 
With FA incorporation range of 0-21.3% within the time range of 0-20 minutes, the rate 
was 1.065%min-1 and the same rate was approximately 1.2 %min-1 with FA incorporation 
range of 34.7-82.7% within the time range of 60-100 minutes. Hence, the rate was low 
within the time range of 0-20 minutes and 100-130 minutes, and high within the time 
range of 0-20 minutes and 60-100 minutes. The growth of rate incorporation of folic acid 
(drug) in the polymer involves the growth of the covalent reversible attachment of the 
carrier through amide bond formation with the folic acid (drug). Thus, the covalent 
reversible attachment of carrier will keep increasing until to reach, if possible, the 
maximum rate incorporation of folic acid in the polymeric carrier.  Consequently, the 
coupling yield will always increase when the covalent reversible attachment is occurring 
as fast as the cleavage of polymer occurs. Dealing with irreversible reaction, the reaction 
between folic acid and the polymeric carrier should result to the growth of the coupling 
yield in terms of time as the rate of incorporation of folic acid in the polymeric carrier is 
increasing.  However the consideration of the Figure 4.3 shows that the fraction of yield 
was moderately increasing in the time range of 0-60 minutes and became accentuated 
until to reach the maximum in the time range of 60-100 minutes, unlikely decreasing in 
the range of 100-130 minutes. The contrast is that the fraction of yield was not increasing 
all the time of reaction with the fraction of incorporation of folic acid as intended. To 
investigate the cause of the contrasting behaviour of the fraction of yield, it was found 
that the polymer with high molecular weight could be subject to cleavage during the 
reaction. Water-soluble polymers, mostly cationic polyelectrolytes, are widely used as 
flocculants. Mineral processing, water clarification, and paper manufacture are some 
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areas where these polymeric flocculants are extensively used (184, 185. The cleavage of the 
intramolecular bonds may be classified in three cases; a) the scission can occur in any 
bonds, b) the cleavage of the main chain occurs in any bonds, after pendant groups break 
first, c) the main chain carbons with the pendant group break in any bonds of the main 
chain. The hydrolytic cleavage, however can occur during the dialysis, can not affect the 
change of yield while both the processes of chromatography and dialysis were observed 
in the same condition of work for every reaction time.  
 
The use of 2-(1H-benzotrial-1-yl)-1,1,3,3-tetramethylurium hexafluorophosphate 
(HBTU) as coupling agent could dispose the polymer to the cleavage of the main chain in 
any bond. This reduces the length of certain long chains, as well as the molecular weight 
respectively. Therefore, during a chromatography process, all chains with molecular 
weight under 5000 can be removed from the solution and further, fewer than 12000 
during the dialysis process.  It resulted in both the decrease of fraction of polymeric 
carrier (Fig. 4.4) and the growth of the fraction of removed polymeric carrier (Fig. 4.5) 
during the reaction time. 
 
Figure 4.7 (series 1 and 2) as combination of Figure 4.2 and Figure 4.3, shows that in the 
same range time of 60-100 minutes the growth of the fraction incorporation of folic (34.7 
82.7%) was more pronounced and the fraction of coupling yield (78.83-84.87%) was 
accentually increasing.  Hence, the incorporation of folic acid in the polymeric carrier 
was a decisive factor to involve the yield of occurred coupling. Though the fraction of 
remaining polymers due to the cleavage was decreasing (Fig. 4.4), this did not involve 
more the yield of coupling as long as the incorporation of folic acid was growing so fast 
than the polymer available for the coupling was decreasing. It is intending that the sites 
available for the covalent reversible attachment of the carrier through amide bond 
formation with the folic acid (drug) are limited to 100% of folic acid incorporation. Since 
the goal is to reach 100% of folic acid incorporation in the polymer, the coupling yield 
will be the result of the optimum reaction time required to reach the maximum 
incorporation. Accordingly, in order to reach the maximum incorporation of folic acid in 
the polymeric carrier, the reaction was kept running over 100 minutes, time related to 
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85% as maximum coupling yield (Fig 4.3). Then, taking the reaction to 96% 
incorporation of folic acid needed 30 minutes more (100-130) within which the yield was 
decreasing. As the incorporation of folic acid was progressing fast than the cleavage of 
polymer until 100 minutes, this caused a rapid reduction of available site capable to 
receive the folic acid into the polymer. Consequently, in the range of time of 100-130 
minutes the fraction of retained polymer decreased more (Fig. 4.4 and Fig. 4.7) and 
relatively the fraction of removed polymers increased in the same way (Fig. 4.5 and Fig. 
4.7). In the time range of 0-60 minutes the fraction of incorporation moderately increased 
because the activity of the coupling agent in the solution increases with the reaction time. 
The activity of HBTU in the reaction was more effective after 60 minutes of reaction due 
to the fact that the incorporation of folic acid was rapidly increasing within the range 
reaction time of 60-100 minutes where the sites available for reversible covalent 
attachment were reduced. Because HBTU as coupling agent has to assure the reaction 
between polymer and drug, the reduction of sites available for the binding after 100 
minutes of reaction has limited the action of coupling agent. Therefore, the incorporation 
of folic acid was moderately increasing. In order to avoid more dropping coupling yield 
due to the polymer cleavage through the over action of HBTU as coupling agent, the 
reaction was asserted to be stopped within the range minutes (120-130) where the rate 
incorporation of folic acid was in the range (90-96%).   
 
The inherent viscosity was increasing with the reaction time (Fig. 4.8 and 4.15) because 
of the incorporation of folic acid (drug) while challenging the solubility of the carrier, 
could make the compound more viscous (Fig. 4.1).  
 
The variation of mol ratio (X/Y) from 17/3 to 4/1 as illustrated in Table 4.9 has led to the 
settlement of different figures. Figure 4.9 confirmed the increase of fraction incorporation 
with the reaction time. The fraction of coupling yield has kept increasing even while 
changing the ratio, and did not decrease anywhere because the range time (60-120) was 
so large, and could not  show exactly the reaction time when the coupling yield was 
decreasing (Fig. 4.10). In Figure 4.11, the fraction of remaining polymers was decreasing 
while the fraction of lost polymers was relatively increasing with the reaction time (Fig. 
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4.11). When compare Figure 4.2 to Figure 4.9, the investigation showed that the carrier 
with mol ratio (4/1) has reached the maximum of the fraction of incorporation of folic 
acid at the record time than the carrier with mol ratio (17/3). The less the mol ratio (X/Y) 
is, the more anchoring drug quantity equivalent to the drug quantity is needed to 
complete the available site. As the reaction kinetics is generally dependent on 
concentration, temperature and catalyses; the excess of the drug, increasing the 
concentration, can have more effect on the reaction kinetics.     
 
The comparison of Figure 4.15 to Figure 4.8 shows that the viscosity when working with 
PSI-DMP (80)-PDA (20)-FA (mol ratio 4/1) is higher than when working with PSI-DMP 
(85)-PDA (15)-FA (mol ratio 17/3). This, because the less mol ratio (X/Y) will need 
more folic acid which being water insoluble, increases the viscosity of the coupling. 
When the mol ratio X/Y decreases, the mol of anchoring drug unit increases, and more 
site for drug incorporation will be available for covalent reversible attachment. Thus, the 
more the compound is insoluble the more its viscosity is higher. 
 
Figure 4.2: Fraction FA incorporation versus reaction time (Mol ratio 17/3) 
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Figure 4.3: Fraction of coupling yield versus reaction time (Mol ratio 17/3) 
 
 
Figure 4.4: Fraction of Retained Polymers versus reaction time (Mol ratio 17/3) 
 
 
 
 
Figure 4.5: Fraction of Removed polymers versus reaction time (Mol ratio 17/3) 
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Figure 4.6: Fraction of FA in coupling versus reaction time (Mol ratio 17/3) 
 
 
 
Figure 4.7: Combining Fractions versus reaction time (Mol ratio 17/3) 
 
 
 
Figure 4.8: Inherent viscosity versus reaction time (Mol ratio 17/3) 
 
 
Series 1: Fraction of FA incorporation in Polymers, series 2: Fraction of coupling yield, series 3: Fraction 
of retained Polymers, series 4: Fraction of removed Polymers, series 5: Fraction of FA in coupling 
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Figure 4.9: Fraction FA incorporation versus reaction time (Mol ratio 4/1) 
 
 
Figure 4.10: Fraction Coupling versus reaction time (Mol ratio 4/1) 
 
 
 
 
Figure 4.11: Fraction of Retained Polymers versus reaction time (Mol ratio 4/1) 
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Figure 4.12: Fraction of Removed Polymers versus reaction time (Mol ratio 4/1) 
 
 
 
 
Figure 4.13: Fraction of FA in coupling versus reaction time (Mol ratio 4/1) 
 
 
 
Figure 4.14: Combining Fraction versus reaction time (Mol ratio 4/1) 
 
 
 
 
 
Series 1: Fraction of FA incorp. in Polymers, series 2: Fraction of coupling yield, series 3: Fraction of 
retained Polymers, series 4: Fraction of lremoved Polymers, series 5: Fraction of FA in coupling 
82 
 
 
Figure 4.15: Inherent Viscosity versus reaction time (Mol ratio 4/1) 
 
 
4.2.1.3. Comparative study of PSI-DMP(X)-PDA(Y)-FA conjugates 
 
After the optimization of the reaction time at 120 and 130 minutes, the coupling obtained 
by varying the mol ratio at 19/1, 17/3 and 4/1, shows the decreasing of yield respectively 
(Table 4.9). The more the mol ratio is big, the more the anchoring drug need for folic acid 
is less. Since the mol of HBTU coupling agent is anchoring drug dependent, the small 
quantity of HBTU need for a big mol ratio (X/Y) will lead to the minimization of the 
polymer cleavage. This corroborates the option that the coupling agent in the reaction of 
polymeric carrier drug conjugate is one of factors capable to promote the polymer 
cleavage.  
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Table 4.9: HNMR spectra data for PSI-DMP (X)-PDA (Y)-FA conjugates 
 
 
Chemical compound 
  
 
X Y X/Y 
HNMR 
Spectra 
Chemical shift δ/ppm 
Calculated (expected) % FA 
Incorp
. 
BMw ηinh 
(mLg-1)
 
Yield 
 
 
% 
8.7-6.75 
Aromatic & 
heteroaromatic 
CH 
1.7-1.6 
CH2CH2CH2  
 
PSI-DMP (X)-PDA (Y)-FA 
95 
85 
80 
5 
15 
20 
19/1 
17/3 
4/1 
7 
20 
25 
5.2 (5) 
14.4 (15) 
5 (5) 
40 (40) 
40 (40) 
10 (10) 
104 
96 
100 
4380.4 
5171.1 
1391.6 
15.81 
22.07 
23.02 
88.53 
83.98 
82.80 
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4.3. Carbon nanotubes drug carriers  
4.3.1. Synthesis of Carbon nanotubes 
The CNTs used in this study are multiwall carbon nanotubes (MWNTs) which are 
prepared by chemical vapour deposition (CVD). In this method, source of Fe catalyst was 
ferrocene which is dissolved in acetylene as a gas carbon source and this gas was carried 
to a synthetic reactor by argon. During synthesis process, amorphous carbon is also 
produced and was removed through the oxidation in the presence of the air. The CNTs 
obtained were refluxed in HNO3 to eliminate the metal catalysis. The results obtained 
after TEM analysis, are illustrated in Figure 4.16.   
4.3.1.1. Results of Synthesis of Carbon nanotubes 
The total yield of multiwall carbon nanotubes (MWCNTs) prepared after 25 experiments 
was 8.56g with the mean yield of 345mg per experiment. The microscopic image from 
the TEM analysis as shown in Figure 4.16, captured with magnification 100000, shows 
tubes with average outer diameter (do) of 20nm and inner diameter (di) of 10nm.  
 
Figure 4.16: MWCNTS microscopic image (TEM)  
4.3.1.2. Discussion of Results of Synthesis of Carbon nanotubes 
The CNTs found could have a variety of applications because of their novel structure, 
especially the small size and remarkable mechanical, thermal and electrical properties. 
Small-diameter MWCNTs have ability to display enhanced reactivity relative to larger-
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diameter nanotubes, due to increased curvature strain. However, because of their novel 
structure of elemental carbon, CNTs are insoluble in all organic solvents. In addition, the 
CNTs found got a very high surface energy with a tendency to aggregate together. This 
makes them difficult to be dispersed. 
Thus, the carbon nanotubes found could be used for many applications. Their 
compatibility with aqueous environments was made possible by chemical 
functionalization of their surface. The functionalized carbon nanotubes, in respect of 
certain requirements such as pH and peptide availability bond, can easily interact with 
biological components including mammalian cells.  
4.3.2. Functionalization of carbon nanotubes 
4.3.2.1. Covalent functionalization of carbon nanotubes 
A. Functionalizationof CNTs with concentrated nitric acid and sulfuric acid           
a). Results of Functionalization of CNTs with concentrated nitric acid and sulfuric acid  
In this study, CNTs were functionalized with H2SO4/HNO3 in mol ratio 3:1 differently at 
100°C, 50°C and room temperature respectively (RT). After TEM analysis the following 
results were recorded:                                                                                                      
With the variation of temperature, at 100ºC the outer diameter (d0) =20nm and the inner 
diameter (din) = 12nm (Fig. 4.17) while at 50ºC do= 30nm (Fig. 4.18) and at room 
temperature (RT) d0= 80nm and din= 40 (Fig.4.19). In order to evaluate the variation of 
the size of f-CNTs in terms of temperature, a graph of diameter versus temperature was 
plotted as shown in Figure 4.20. 
The water solubility of f-CNTs was decreasing from 100°C to RT especially from pH = 9 
and above.   
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Figure 4.17: f-CNTs ( H2SO4/HNO3 at 100⁰C) microscopic image 
 
 
Figure 4.18: f-CNTs (H2SO4/HNO3 at 50⁰C) microscopic image 
 
 
Figure 4.19: f-CNTs (H2SO4/HNO3 at RT) microscopic image 
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Figure 4.20: Size of CNTs versus temperature 
The analysis of 1H NMR Spectra 26, 27, 28 (in appendix) done for f-CNTs obtained at 
different temperatures including 100°C, 50°C, RT respectively shows peaks A and B in 
chemical shift δ/ppm (1.5-2.5) for –CH2COOH and (2.7-3.7) for –CH2OH. In order to 
calculate the quantity of COOH and OH, the integration of peak A (–CH2COOH) 
corresponding to 1 mol was used as reference to evaluate the peak B (–CH2OH). After 
calculation, the following results were obtained: 
1) The integration of peaks A and B in 1H NMR Spectra (26) for f-CNTs (100ºC) shows 
after evaluation that 1 mol of COOH adsorbed on the surface of MWCNTs, 
corresponded to 7.54 moles of OH.   
2) The integration of peaks A and B in 1H NMR Spectra (27) for f-CNTs (50ºC) shows 
after evaluation that 1mol of COOH absorbed on the surface of MWCNTs, 
corresponded to 2.27 mol of OH. 
3) The integration of peaks A and B in 1H NMR Spectra (28) for f-CNTs (RT) shows 
after evaluation that 1 mol of COOH absorbed on the surface of MWCNTs, 
corresponded to 0.08 mol of OH.  
 
A sample of 200mg of f-CNTs was used for titration to evaluate the quantity of COOH in 
mmol incorporated on the surface of f-CNTs which through the mol ratio COOH/OH 
calculated from different 1H NMR spectra integration was used to calculate the quantity 
of OH in mmol incorporated on the surface of f-CNTs. The experimental data from 
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titration was used through the formula Y= 1-0.04Xe to complete the Table 4.10 shown 
below. The graphs include the data from the Table 3.10 were plotted to show the 
evolution of both the fraction of incorporation of COOH and OH versus the temperature 
as shown in Figure 4.22 and the mol ratio COOH/OH versus the temperature as shown in 
the figure  4.23.    
Different peaks including A, B, C, D and E were shown in the infrared (IR) investigation 
as presented in Figure 4.21(a) and (b). 
A: O-H stretch, (3331.44 cm & 3334.86 cm) intermolecular hydrogen bonded  
B: C-H stretch; (2892.90cm & 2902.20 cm)   
C: C=O, stretch; (1693.04 cm & 1716.56 cm) 
D: C-O (1158.92 cm-1- 1028.01 cm-1) & (1156.39 cm-1-1030.67 cm-1), stretch 
E: Ring C=C, bend, (663.67 cm-1-574.56 cm-1), this confirm the CNTs the graphene 
structure with sp2 -bond carbon. 
   
 
     
 
 
 
 
 
                                                 
e
 Y is the quantity of COOH in mmol incorporated on the surface of f-CNTs and X is the volume of HCl in 
ml 
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Table 4.10: Fraction incorporation of COOH and OH on the surface of CNTs with 
variable temperature 
 
TºC 25ºC (RT) 50ºC 
 
100ºC 
 
Mass of f-CNTs 200mg 200mg 
 
200mg 
 
nH: COOH 1 1 
 
1 
 
nH: OH 0.08 2.27 
 
7.54 
 
X ml 16ml 13ml 
 
6ml 
 
Y mmol 0.36mmol 0.48mmol 
 
0.76mmol 
 
% COOH incorp. 8.1% 10.8.% 
 
17.1% 
 
% OH incorp. 0.25% 9.9% 
 
48.7% 
 
 
nH: number of Hydrogen atom,  
X: the volume of HCl in ml   
Y: the quantity of COOH in mmol incorporated on the surface of f-CNTs 
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Figure 4.21(a): Infrared Peaks of f-CNTs (H2SO4/HNO3) at 50°C 
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Figure 4.22(b): Infrared Peaks of f-CNTs (H2SO4/HNO3) at 100°C  
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b) Discussion of Results of Functionalization of CNTs with concentrated nitric acid and 
sulfuric acid 
 
Figure 4.20 elaborated from the TEM results (Fig. 4.17, 4.18 and 4.19), shows the 
increase of the size of nanotubes when the temperature was decreasing. This is because 
self-diffusion of guest molecules inside of CNTs can be possible. The carbon nanotubes 
(CNTs) can be aligned to form a well-ordered nanoporous membrane (186, 187), which can 
be incorporated in a macroscopic structure (188) for separation devices. The study of self-
diffusivity can explain well the influence of nanotube sizes and temperature. Yashonath 
and co-workers had examined this effect in more detail for diffusion zeolites (189, 190) 
using molecular dynamics simulations. They termed this behaviour the “Levitation 
effect”. If the guest molecule fits perfectly in the window of the zeolite, the molecule 
appears to be “floating”; increasing or decreasing the diameter of the guest molecules 
causes the diffusion coefficient to decrease. This effect is temperature dependent (191). A 
similar effect has been observed by Bride et al. (192) for carbon nanotubes.  
 
With regard to Figure 4.20, the self-diffusivity was subsequently increasing with the 
decreasing of temperature. Since the self-diffusion explains the incorporation of guest 
molecule in CNTs through nanoporous membrane, the diameter of CNTs has to increase 
in the tendency where the self-diffusion will increase. It results in the increase of 
diameter with the decrease of temperature as shown in figure 4.20. Regarding the 
objective to develop the surface of CNTs for further utilization, more importance was 
given to the trend where the adsorption (surface phenomenon) was possible, rather than 
where absorption was evident. The increase of temperature, causing the diameter to 
decrease, led to higher collision frequencies due to faster motion. In addition, the 
probability to find a particle close to the pore wall is enhanced (higher collision 
probability). In order to have the drug  (folic acid) bonded on the surface of CNTs, the 
functionalized carbon nanotubes (CNTs) made at 100°C were selected, due to their small 
size and the adsorption developed on their surface. 
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 The 1H NMR Spectra 26, 27 and 27 were obtained with D2O as solvent. Therefore 
COOH group and OH group directly attached on the surface of CNTs were shifted in 
δ/ppm (4.5-5.5) for D2O peaks. Expecting to get f-CNTs covered on surfaces only with 
COOH and OH groups as shown in Scheme 2.4, the 1H NMR analysis for all f-CNTs 
made at different temperatures (100ºC, 50ºC and RT) have shown the presence of 
CH2COOH and  CH2OH. This has guided to set the structure as shown in Scheme 4.4. 
More investigation was needed to disclose the cause of the presence of CH2COOH and 
CH2OH on the surface as well as COOH and OH as shown in the scheme 4.4. When the 
purification stage is not reliable, there is possibility to have the amorphous carbon mixed 
with carbon nanotubes. The purification of pristine made using HCl (32%) and further the 
presence of HNO3 (55%) in the operation of functionalization were enough to remove the 
amorphous carbon. Dravid et al. (193), however, suggested an alternative model described 
as ‘paper roll’ where nanotubes are composed of spiral scrolls of graphene sheets. 
Amelinckx (194) has proposed an intermediate model where the nanotubes consist of 
cylindrical sheets, with scrolls of constant helicity interspersed between them.             
This structure as presented, grants to CNTs an exceptional mechanical property           
that their high degree of stiffness combines with resilience, and the ability to                   
buckle and collapse in a reversible manner: even largely distorted configurations                                        
(axially compressed, twisted) can be due to elastic deformations with virtually no atomic 
defects involved (195, 196, 197, 198). 
The motion of dislocation edges in a strained structure is a well-known phenomenon in 
the theory of dislocations. This can cause as well the crack of some hexagonal symmetry 
C-C in order to have simple carbon attached to other hexagonal, keeping the nanotubes 
structure. Indeed, the presence of strong acid for CNTs functionalization can cut the tubes 
in shorter pieces and generate carboxylic functions at the tips and around the sidewalls 
where the curvatures of the tubes present a higher strain. 
In addition, the infrared analysis from Figure 4.21(a) and (b), and the 1H NMR Spectra 
26, 27 and 28, have confirmed that the produced f-CNTs was constituted of MWNTs 
covered on the surface with CH2OH and CH2COOH and with OH and COOH as shown 
in Scheme 4.4. 
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Scheme 4.4: f-CNTs (H2SO4/HNO3) structure. 
In comparison with the result from Figure 4.22, it was found that both fractions of OH 
and COOH incorporation in f-CNTs were increasing with the increase of temperature.   
At room temperature, the fraction of OH group incorporation was much neglected and the 
mol ratio COOH/OH was 32.4, this was rapidly reduced to 1.1 at 50ºC until dropping 
down to 0.35 at 100°C. It means that though the weak presence of OH in f-CNTs at room 
temperature, this increased very rapidly when the temperature started increasing.        
This shows that when working at room temperature or below there is possibility of 
getting f-CNTs covered only with COOH. 
  
The OH (phenol group) is a polar group, and plays an important role for water solubility 
of the functionalized carbon nanotubes. It was experimentally proved that the f-CNTs 
obtained at 100°C, having more mol of OH on the surface, was more soluble in water 
than those obtained below 100°C. Thus, the abundance of OH and COOH groups on the 
surface will facilitate more covalent attachment to polymers or drugs according to their 
different electronegativities. This granted the f-CNTs made at 100ºC to be more useful 
than those made at low temperatures. The scope of this reaction was very broad and 
produces f-CNTs that possess high solubility in a wide range of different solvents.      
This was preferentially selected for the next phase of the drug binding to carbon 
nanotubes. 
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Figure 4.23: Fraction of COOH & OH group incorporation versus temperature 
 
Series 1: Fraction incorporation of carboxyl group (COOH) on the surface of CNTs. 
Series 2: Fraction incorporation of phenol group (OH) on the surface of CNTs. 
 
Figure 4.24: Mol rate COOH/OH versus temperature 
  
B. Functionalization of CNTs with Aspartic acid  
The functionalized carbon nanotubes (f-CNTs) were also obtained by heating MWNTs 
with aspartic acid as amino acid in DMF at 220ºC. This resulted to the structure as shown 
in Scheme 4.5.  
a) Results of f-CNTs by Aspartic acid  
After collecting a yield of 183mg soluble in water from pH 10, different analysis were 
performed to investigate the sample obtained. 
The microscopic image obtained after TEM analysis confirmed the nanotube structure 
with the diameter of 60nm as shown in Figure 4.24.   
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Figure 4.25: f-CNTs (MWNTs +Aspartic acid in DMF at 220⁰C) 
The 1H NMR Spectra 29 (in appendix) showed peaks A in chemical shift (δ/ppm) 3.050-
2.200 for –CH2COOH and B in chemical shift (δ/ppm) 4.40-4.70 for =N-CH CH2 
(COOH)
 2 as expected.   
Different peaks including A, B, C, D, E, F and G were shown in the infrared (IR) 
investigation as presented in Figure 4.25. 
A: N-H stretch, at 3331.44 cm-1.                                                                                               
B: C-H stretch in the region  3015.95-2902.20cm-1                                                            
C: Overtone region usually contains a prominent band in the region 2337.23-2119.11cm-1   
D: C=O bond stretch, at 1738.63 cm-1                                                                                
E: C-N stretch, at 1436.30cm-1                                                                                            
F: C-O (acetate) stretch, in the region 1228.93-1216.70 cm-1                                                                  
G: O-H out of plane bend, 1011.82-912.05 cm-1  
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Figure 4.26: IR f-CNTs (aspartic acid) 
 
Using titration formula Y= 1-0.04Xf, when working with 200mg of f-CNTs 0.88 mmol of 
COOH corresponding to 20% of COOH was incorporated on the surface of CNTs after 
the neutralization of excess NaOH with 3ml of HCl. The carboxyl group incorporated in 
the f-CNTs was intended to be bound with the solubilising group and the drug. Then the 
quantity of solubilising group and drug will be evaluated in terms of 20% of fraction of 
COOH in f-CNTs. The test of solubility showed that the f-CNTs obtained were water 
soluble at pH =10. The attachment to a solubilising group was beneficial to increase the 
solubility.  
                                                 
f
 Y is the quantity of COOH in mmol incorporated on the surface of f-CNTs and X is the volume of HCl in 
ml 
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b) Discussion of Results of f-CNTs by Aspartic acid  
The diameter of f-CNTs obtained from MWNTs heated at 220⁰C in aspartic acid with 
DMF was 60nm. This was bigger than the diameter obtained for MWNTs in sulfuric and 
nitric acids at 100°C and 50°C, and lesser than MWNTs in sulfuric and nitric acids at RT. 
According to the findings from Figure 4.20, the diameter was decreasing with the 
increase of temperature. At 220°C as a very high temperature, the diameter should be 
very small. To explain this contrast, Derouane and co-workers (199, 200) were the first to 
mention an enhanced mobility for cases where the dimensions of guest particles match 
closely the host structure dimensions. They called this effect the “floating molecule”. 
When the temperature rises to very high, the dimension of the diameter of the guest can 
increase or decrease and affects the diffusion coefficient. The diameter of f-CNTs 
obtained differently when varying molecules at different temperatures, was attributed to 
the phenomena of guest molecules inside CNTs in detail by means of molecular 
dynamics simulation.  
The investigation of peaks in 1H NMR Spectra 29 and infrared (IR) as shown in      
Figure 4.25 confirmed the structure elaborated in Scheme 4.5. 
 
Scheme 4.5: f-CNTs (aspartic acid) structure 
 
Overall, the use of strong acid and amino acid to functionalize the carbon nanotubes 
generates carboxylic groups (Schemes 4.4 and 4.5), which increase their dispersibility in 
aqueous solutions (201).  Solubility under physiological conditions is a key prerequisite to 
make CNT biocompatible. In addition, functionalised carbon nanotubes (f-CNTs) can be 
linked to a wide variety of active molecules, including peptides, proteins, nucleic acids 
and other therapeutic agents.   
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4.3.2.2. Noncovalent functionalization of carbon nanotubes 
 
The poly-DL-succinimide, due to the ability to provide ring-opening process when 
applying one type of amine reactant, was selected as polymer to make noncovalent 
functionalization of carbon nanotubes. The opening-ring through the application of both 
solubilizing group and drug anchoring site were necessary to provide long side chains. 
Consequently, the coating molecules could present functional groups available for 
bioconjugation with peptides or other molecules such as amines, to create various 
functional CNT conjugates for different biological applications. 
 
A. Results of Noncovalent functionalization of carbon nanotubes 
The functionalization of carbon nanotubes (scheme 4.6) was done at 160ºC via the 
dissolution of poly-DL-succinimide in DMF, the solution wherein CTNs were dispersed. 
The yield was 216mg. The product was partially water soluble at pH=10. The sample was 
submitted to different analysis to investigate the quality of f-CNTs.  
The TEM analysis recorded in Figure 4.26 showed that CNTs were covered with poly 
D.L. succinimide to make f-CNTs with outer diameter of do= 60nm and inner diameter of 
din= 40nm.   
 
Figure 4.27: f-CNTs (Polysuccinimide) microscopic image 
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Three peaks were shown in the 1H NMR Spectra 30 which corresponds to f-CNTs    
(Polysuccinimide), and the chemical shifts (δ/ppm) related to those peaks were analysed 
as follow: 
A: (3.030-2.650) confirmed the expected group band –CO-CH2- with 2H expected. 
B: (4.5-4.45) confirmed the expected group band CH-N with 0.82 H calculated while 1H 
was expected.  
C: 7.940, showed H in aromatic region. 
Different characteristic peaks were shown in the infrared (IR) analysis as presented in  
Figure 4.27. 
a) The  characteristic absorption peaks appear at 2941.63 cm-1, due to C-H vibration, 
and at 1707.82 cm-1, due to C=O vibration of poly-DL-succinimide.  
b) The characteristic peaks at 1654.53 cm-1, due to C=C on the end cap.  
c) The peaks at 1387.39 cm-1 are due to C-N stretch.  
d) The characteristic peaks `at 1211.25 cm-1, and at 1164.00 cm-1, due to C-C 
stretching vibration.  
e) The peaks at 694.79 cm-1and 633.12 cm-1, due to C=C of carbon nanotubes with 
graphene structure.   
 
B. Discussion of results of Noncovalent functionalization of carbon nanotubes 
The dark part in Figure 4.26 related to TEM analysis confirmed the coating molecule on 
the carbon nanotubes surface. 
The H of aromatic group of peak C shown in 1H NMR Spectra 30 was not expected to be 
appeared though the number of H calculated is negligible (0.05H). It was defined in 
section 4.3.2.1 that the CNTs were structurally constituted of graphene (graphite-ene) and 
the rupture of nanotubes started to occur at the end cap which after dislocating the C-C of 
some hexagonal. To achieve the electronic configuration, an H should be attached to 
carbon (C=C) stayed in hexagonal. In addition, the nanotubes are very vulnerable at the 
cape more than anywhere else. The use of an ultrasonic bath to disperse f-CNTs could 
sometimes be the cause of a rupture of some link C-C in hexagonal on the end cap.  
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Definitively, the peaks A, B as illustrated in 1H NMR Spectra 30 confirm the structure 
detailed in the Scheme 4.6.  
The infrared (IR) in Figure 4.27 has shown all the expected peaks as the structure 
illustrated in Scheme 4.6.   
 
Scheme 4.6: f-CNTs (Polysuccinimide) 
 
 
 
Figure 4.28: IR f-CNTs (Polysuccinimide) 
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4.3.3. Functionalized carbon nanotubes (f-CNTs) bound Folic acid conjugates  
 
The carboxyl group found after developing the covalent functionalization of carbon 
nanotubes (Schemes 4.4 and 4.5) was attached to the amines to generate the peptide 
group for further use. The tertiary amine was attached through carboxyl group at a certain 
mol ratio to enhance the solubility of the f-CNTs. With respect to cover the total ratio to 
100%., the folic acid was added to complete the electronic configuration. The choice was 
made on 3-dimethylamino-1-propylamine (DMP) as a strong base; this can render the 
amino group positively charged by carrying more cationic, and will preferentially 
approach surfaces of certain types of cancer cells that are negatively charged.  
 
Since the noncovalent functionalization was developed by coating CNTs with poly-DL-
succinimide (Scheme 4.6), the opening of the ring was required to enhance water-
solubility and provide available site for anchoring of the drug. This was completed by the 
application of 3-dimethylamino-1-propylamine (DMP) as solubilizing group and 1, 3-
propylenediamine (PDA) as drug anchoring site. 
 
4.3.3.1. f-CNTs (H2SO4+HNO3 at 100˚C) bound folic acid conjugates 
 
Given that the estimation of the percentage of –COOH in a quantity of f-CNTs was done 
by the titration, the assessment of the quantity of DMP and folic acid was rendered 
possible. In fact, the reversible covalent attachment was achieved by the reaction between 
–COOH and NH2 via the coupling agent 0-benzotiazol-1-yl-tetramethylurorium 
hexafluorophosphate (HBTU). With the objective to raise the water solubility of f-CNTs, 
30% of –COOH was evaluated to be attached to DMP as solubilizing group. Therefore 
the folic acid was used in excess with the objective to complete all the 70% of -COOH 
that did not react with DMP. The removal of excess folic acid was made possible by 
washing the solid obtained with tetramethylurea (TMU) dissolving free folic acid. Thus, 
the achievement of this reaction has led to the product with the yield of 163mg, and the 
chemical structure is presented in Scheme 4.7. Several tests were performed including 
water-solubility, TEM and 1H NMR analysis.  
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A. Results of f-CNTs (H2SO4+HNO3 at 100˚C) bound folic acid conjugates 
The water-solubility was successful at pH 6-7, while the TEM analysis of Figure 4.28 
gave d0=50nm and din=20nm and 1H NMR Spectra 31 confirmed the expected peaks with 
chemical shift shown in Scheme 4.7 as illustrated in Table 4.11. 
 
 
Figure 4.29: f-CNTs (H2SO4/HNO3)-FA 
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Table 4.11: HNMR spectra of f-CNTs (H2SO4/HNO3)-FA 
 
Chemical Shift 
δ/ppm 
1H NMR 
peacks 
identification 
Assignment 
8.60-6.75 G, F, E CH Aromatic 
 
4.85 -4.28 C 
 
CH Asp, CH Folic 
acid and CH2OH 
3.25-2.75           D 
 
 
-CONHCH2, NHCH2, 
-CH2NH 
2.25-1.8 B 
 
 
-CH2COOH,         
CH2CONH, 
NH(CH3)2 
1.8-1.7 A 
 
 
COOHCH2CH2CH,  
CH2CH2CH2 
 
B. Discussion of results of f-CNTs (H2SO4+HNO3 at 100˚C) bound folic acid 
conjugates                                                                                                   
The coupling obtained after conjugation of folic acid to f-CNTs (Scheme 4.7) has 
completed the nanotubes shape as shown in Figure 4.28. The micrograph image showed 
the dark color at the end cap of the nanotubes; this is due to the attachment through the 
amide formation of the covalent reversible attachment of the f-CNTs with the drug. With 
the size of 50nm as outer diameter and 20nm as inner diameter the conjugate can be 
easily tracked into the cytoplasm and the nucleus.  
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With regard to the 1H NMR Spectra (31), the fraction of incorporation of folic acid was 
calculated by using the integration of A that is 1 and the sum of integration of aromatic 
group E, F and G which is 1.64. With 30% of DMP and 70% of folic acid, the mol ratio 
was 3/7 and the number of H expected was 20H for A and 35H for the sum of E, F, and G 
as it is shown in the structure (Scheme 4.7). Referring to A as 20H calculated with 
integration 1, the sum of E, F and G with integration of 1.64 gave 32.8H calculated which 
corresponded to 94% incorporation. 
 
Scheme 4.7: f-CNTs (H2SO4/HNO3)-DMP (30)-FA (70) Structure 
 
4.3.3.2. f-CNTs (Aspartic acid) bound folic acid conjugates 
 
In this case, the estimation of the percentage of –COOH in a quantity of f-CNTs was also 
evaluated by the titration; and it was possible to assess the necessary quantity of DMP 
and folic acid. In fact, the reversible covalent attachment was achieved by the reaction 
between –COOH and NH2 via the coupling agent 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium fluorophosphates (HBTU). With the objective to raise the water 
solubility of f-CNTs, 40% of –COOH was evaluated to be attached to DMP as 
solubilizing group. Thus, the fraction of solubilising group was bigger than that attached 
in section 4.3.3.1, because the previous f-CNTs were more soluble than the later f-CNTs 
when both considered in their initial condition. Therefore the folic acid was used in 
excess with the objective to complete all the 60% of -COOH that did not react with DMP. 
The removal of excess of folic acid was made possible by washing the solid obtained 
with tetramethylurea (TMU) which could dissolve all free folic acid in the solution.  
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A. Results of f-CNTs (Aspartic acid) bound folic acid conjugates 
This reaction gave a product with the yield of 231mg, and the chemical structure is 
presented in Scheme 4.8. Several tests were performed including water-solubility, TEM 
and 1H NMR analysis. The water-solubility was successful at pH 6-7. 
 
After TEM analysis, the average diameter of nanotubes in Figure 4.29 was evaluated to 
170nm.  
 
 
Figure 4.30: f-CNTS (Aspartic acid)-DMP (40)-FA (60) microscopic image 
 
The 1H NMR Spectra (32) showed all expected chemical bands as illustrated in         
Table 4.12. Thus, this confirms that the reversible attachment between f-CNTs with DMP 
and folic acid was possible via the formation of amide group. To calculate the fraction 
incorporation of folic acid, the integration of peak A evaluated to 1 was chosen as 
reference and corresponded to 4H as expected, and the integration of aromatic peaks     
(E, F, G) evaluated to 3.8 was calculated 15.2H while the expected was 15H as shown    
in Scheme 4.8, and then the fraction incorporation of folic acid was 101.3%.                    
The error was 1.3%.   
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Scheme 4.8: f-CNTs (Aspartic acid)-DMP (40)-FA (60) Structure 
 
Table 4.12: HNMR data f-CNTs (aspartic acid)-DMP (40)-FA (60) 
Chemical Shift 
δ/ppm 
1HNMR 
peaks 
identification 
Assignment 
 
8.7-6.8 
 
G, F, E 
 
CH Aromatic 
4.7-4.25 D 
 
CH Asp,  
CH Folic acid 
3.2-2.9 C 
 
-CONHCH2, NHCH2, 
CH2NH(CH3)2 
2.3-1.8 B 
 
-CH2COOH,         
CH2CONH, 
COOHCH2CH2CH 
 
1.8-1.7 
 
A CH2CH2CH2 
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B. Discussion of results of f-CNTs (Aspartic acid) bound folic acid conjugates 
With small size of 170nm, the f-CNTs-drug conjugate, being biocompatible, can easily 
penetrate the cells until the delocalisation of cancerous cells for the release of the drug to 
the target. The f-CNTs-drug conjugate from aspartic acid (Fig. 4.29) showed the dark 
spot spread along the nanotubes while Figure 4.28 related to the f-CNTs of conjugate 
made from H2SO4/HNO3 at 100˚C has shown more dark spot at the end cap 
comparatively. Since in section 4.3.2.1 the incorporation of COOH (17.1%) in f-CNTs 
with H2SO4/HNO3 at 100˚C (Table 4.10) was lesser than the one (20%) in f-CNTs with 
aspartic acid, more quantity of DMP and folic acid will be needed in total to cover all the 
carboxyl group, and this can result to a structure with nanotube more dark.  
 
4.3.3.3. f-CNTs (Poly-DL- succinimide) bound folic acid conjugates 
  
The f-CNTs for this case was obtained by coating the MWCNTs with the polymer poly-
DL-succinimide whose opening of the ring required the attachment of DMP and PDA in 
a certain proportion. The attachment of both DMP as solubilising group and PDA drug 
anchoring site led to the formation peptide groups able to reinforce the antibody. The 
challenge was to evaluate the quantity of polymer coated to the MWCNTs for 
functionalization, accordingly to determine the quantity of DMP and PDA. In order to 
ensure more space for the anchoring drug the mol ratio was 40% for solubilising group 
(DMP) and 60% for drug anchoring site (PDA). The reaction was running at below room 
temperature while PDA was added in excess and drop-wise. This could prevent the 
crosslinking capable to occur during the reaction. After elimination of excess of PDA by 
washing with hot toluene and then hot acetone, folic acid was added in excess relative to 
the quantity of PDA.  
 
A. Results of f-CNTs (Poly-DL- succinimide) bound folic acid conjugates 
After the collection of a product with a yield of 35mg, different tests were performed 
including water-solubility, TEM and 1H NMR analysis. The water-solubility was 
successful at pH 6-7.while the TEM analysis gave Figure 4.30 with outer diameter       
(do) of 80nm and inner diameter (di) 40nm, and 1H NMR Spectra 33. 
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After TEM analysis, the evaluation of micrograph image (Figure 4.30) confirmed the 
nanotubes structure of 80nm as outer diameter and 40nm as inner diameter, with the 
presence of lines in transversal of nanotubes.  
 
Figure 4.31: f-CNTs (PSI)-DMP (40)-PDA (60)-FA microscopic image 
 
The 1H NMR Spectra (33) showed different peaks as follows: 
A: - CH2-CH2-CH2; B: CH2-N (CH3)2; NH2CH2; CONHCH2; C: CH2CONH;               
D: COCHNH and E, F, G: H aromatic. 
To calculate the fraction incorporation of folic acid, the integration of pick A evaluated to 
1 was chosen as reference and corresponded to 10H as expected, and the integration of 
aromatic peaks (E, F, G) evaluated to 1.58 was calculated 15.8H while 15H was expected 
according to the Scheme 4.10. This has resulted to the fraction incorporation of folic acid 
of 105.3% with the error of 5.8%.      
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B. Discussion of results of f-CNTs (Poly-DL- succinimide) bound folic acid 
conjugates 
The presence of lines in transversal of nanotubes has shown that MWCNTs have been 
coated with polymer bound folic acid (drug). This confirms the theoretical structure that 
was previously illustrated in Figure 2.1. When taking in to account both the average 
weight of polymer which can prevent the layer of the drug in the kidney, and the small 
size of nanotubes which can facilitate the translocation of the drug in the cell, the 
synthetic polymer bound folic acid (methotrexate) coating the CNTs are more beneficial 
in therapy to improve the condition of drug uptake in the cells.  All chemical bands 
shown in Scheme 4.9 were illustrated in the 1H NMR Spectra (33). 
 
Scheme 4.9: f-CNT (PSI-DMP (40)-PDA (60))-FA structure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
 
CHAPITER 5 
 
 
CONCLUSION AND RECOMMENDATIONS 
 
 
5.1     Conclusion 
 
The current research was undertaken to investigate the formation of biofissionable amide 
in polymer and carbon nanotubes bound folic acid and methotrexate. Considering the 
structural approach of MTX (Schemes 1.1) as compared to folic acid (Schemes 1.2) 
which is very expensive, folic acid was used as drug and the results were comparable to 
MTX drug. In order to prove the formation of bioreversible bond (CONH) between the 
polymer and the drug, the kinetics study was found necessary. This was achieved since 
the incorporation of folic acid in polymeric carrier evolved the time of reaction. 
 
The polymer has been chosen as drug carrier due to its molecular weight capable of 
preventing high concentration of drug in the kidney. Carbon nanotubes, taking advantage 
of its small size capable of penetrating the cell membrane, has also been utilized as drug 
carrier to reach the target. Especially when the carbon nanotube is covered on the surface 
by a polymer bound to the drug, more advantage can be held up relating to the small size 
and molecular weight. Therefore, the primary objective of this research was the use of 
carbon nanotubes as drug carrier as compared to polymeric drug carrier.       
 
The completion of this research was possible through the functionalization of both 
polymeric and carbon nanotubes carriers in respect of certain requirements, capable of 
rendering the drug conjugates bioactive through covalent attachment.  
 
To realize the total functionalization, X% of Polyaspartamide was covered with              
3-dimethylamino-1-propylamide (DMP) and Y% as outstanding available site was 
covered with 1,3 diaminopropane (PDA). This was done by varying the mol ratio X/Y 
(19/1, 9/1, 17/3 and 4/1) which led to 94%, 98%, 102% and 101% incorporation of PDA 
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in the polymer respectively after NMR analysis. In addition, a variety of polymers were 
chosen to be conjugated to folic acid. This was made possible by using an ester, 2-(1H-
benzotrial-1-yl)-1,1,3,3-tetramethylurium hexafluorophosphate (HBTU), as coupling 
agent. The challenge is that the long chain can be subjected to cleavage during the 
reaction. The kinetic study was found necessary to optimize the time of reaction for a 
minimum cleavage with a maximum incorporation of folic acid giving an optimum yield. 
Thus, the time of reaction was set within the range of 120 to 130 minutes. In this time, 
the incorporation of folic acid varyied between 90% and 104% for a yield within the 
range of 80 to 85%.  
 
The carbon nanotubes, due to its small size, were also used as drug carrier to the target. 
Two methods have been developed to functionalize the carbon nanotubes, and these 
included covalent and noncovalent functionalization. The covalent functionalization was 
developed on the surface of CNT the carboxyl group that was able to react through 
HBTU as coupling agent with the amines of DMP in one part and folic acid in other part. 
The formation of CONH as bioreversible bond between the f-CNTs and folic acid has 
been investigated by the use of 1H NMR and IR analysis. This was successful, especially 
when after the enhancement of water solubility the nanotube shape of the structure has 
been conserved within the diameter range of 50nm to 170nm after TEM investigation. 
Particular attention was to f-CNT prepared with CNT dispersed in the mixture of 
sulphuric acid and nitric acid at variable temperatures. The phenol (OH) and carboxyl 
(COOH) groups were attached on the surface of CNT making the rate COOH/OH to 
decrease with increasing temperature. Hence, the f-CNT covered on the surface with OH 
and COOH was more water soluble than the f-CNT covered with COOH.      
 
In order to achieve the noncovalent functionalization, the polysuccinimide was added to 
the carbon nanotubes and thereafter DMP as solubilising group and PDA as drug 
anchoring site were both used for the polymer ring-opening. The f-CNT obtained was 
subjected to 1H NMR, IR and TEM analysis. After analysis, selected f-CNTs were bound 
to folic acid through HBTU. This led to the folic acid carrier conjugation with formation 
of CONH as biofissionable bond investigated after 1H NMR analysis. The TEM result 
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has illustrated the conservation of nanostructure with the diameter of 80nm. The f-CNTs 
functionalized with polymer can be more beneficial as drug carrier due to the small size 
and the high average molecular weight.    
 
5.2     Recommendation 
 
There are many recommendations which can be made both to improve the current work 
and to extend it somewhat further into new areas of research. 
 
5.2.1. Recommendation for the current work 
 
These recommendations are necessary for the improvement of this work: 
• The polymer carrier has to be water soluble at pH within the range 6 and 7. 
• In order to provide a maximum incorporation of folic acid, the polymeric carrier 
has to be conserved in the anhydrous desiccators.  
• The required quantity of HBTU as coupling agent must be in the ratio of 1:1.1 
(carrier:HTBU) because a large quantity can cause more cleavage of polymer. 
• The sonication was useful for the dispersion of carbon nanotubes in the solvent, 
but it must be observed in a short time, approximately 15 minutes to prevent the 
carbon nanotubes from being brittle.   
• To prevent destruction of nanotubes, the functionalization of carbon nanotubes 
using the mixture of sulphuric acid and nitric acid must not go beyond 4 hours 
when working at 100⁰C.   
 
5.2.2. Recommendation for further work 
 
This was not sufficient to conclude that the prodrugs obtained using polymer or carbon 
nanotubes as carriers, could easily penetrate the cell membrane and release the drug to 
the target because no biomedical evaluation has been done. Therefore it is recommended 
that future work be focused on investigating the cytotoxic performance of carbon 
nanotubes carrier drug conjugates.  
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The phenol group and carboxyl group generated on the surface of f-CNTs made with the 
mixture of sulphuric acid and nitric acid can be a subject of selection of drugs due to their 
different electronegativities. Hence the application of different drugs for a good selection 
is recommended for future work.   
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1H NMR SPECTRA 
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1H NMR SPECTRA (1): PSI-DMP (90)-EDDA (10) 
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1H NMR SPECTRA (2): PSI-DMP (80)-EDDA (20) 
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1H NMR SPECTRA (3): PSI-DMP (95)-PDA (5) 
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1H NMR SPECTRA (4): PSI-DMP (90)-PDA (10) 
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1H NMR SPECTRA (5): PSI-DMP (85)-PDA (15) 
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1H NMR SPECTRA (6): PSI-DMP (80)-PDA (20) 
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1H NMR SPECTRA (7): PSI-DMP (95)-PDA (5)-FA 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
147 
 
                                                                                                                                                 
1H NMR SPECTRA (8): PSI-DMP (85)-PDA (15)-FA 
(After 10 minutes of reaction) (8% FA incorporation) 
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1H NMR SPECTRA (9): PSI-DMP (85)-PDA (15)-FA 
After 20 minutes of reaction (21.3% FA incorporation) 
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1H NMR SPECTRA (10): PSI-DMP (85)-PDA (15)-FA 
After 30 minutes of reaction (26.7% FA incorporation) 
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1H NMR SPECTRA (11): PSI-DMP (85)-PDA (15)-FA 
(After 40 minutes of reaction) (29.3% FA incorporation) 
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1H NMR SPECTRA (12): PSI-DMP (85)-PDA (15)-FA 
After 50 minutes of reaction (32% FA incorporation) 
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1H NMR SPECTRA (13): PSI-DMP (85)-PDA (15)-FA 
After 60 minutes of reaction (34.7% FA incorporation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
153 
 
                                                                                                                                                 
1H NMR SPECTRA (14): PSI-DMP (85)-PDA (15)-FA 
(After 70 minutes of reaction) (48% FA incorporation) 
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1H NMR SPECTRA (15): PSI-DMP (85)-PDA (15)-FA 
(After 80 minutes of reaction) (53.3% FA incorporation) 
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1H NMR SPECTRA (16): PSI-DMP (85)-PDA (15)-FA 
(After 90 minutes of reaction) (61.3% FA incorporation) 
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1H NMR SPECTRA (17): PSI-DMP (85)-PDA (15)-FA 
(After 100 minutes of reaction) (82.7% FA incorporation) 
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1H NMR SPECTRA (18): PSI-DMP (85)-PDA (15)-FA 
(After 110 minutes of reaction) (85.3% FA incorporation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
158 
 
                                                                                                                                                 
1H NMR SPECTRA (19): PSI-DMP (85)-PDA (15)-FA 
(After 120 minutes of reaction) (90.6% FA incorporation) 
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1H NMR SPECTRA (20): PSI-DMP (85)-PDA (15)-FA 
(After 130 minutes of reaction) (96% FA incorporation) 
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1H NMR SPECTRA (21): PSI-DMP (80)-PDA (20)-FA 
After 10 minutes of reaction 
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1H NMR SPECTRA (22): PSI-DMP (80)-PDA (20)-FA 
After 25 minutes of reaction 
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1H NMR SPECTRA (23): PSI-DMP (80)-PDA (20)-FA 
After 50 minutes of reaction 
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1H NMR SPECTRA (24): PSI-DMP (80)-PDA (20)-FA) 
After 60 minutes of reaction 
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1H NMR SPECTRA (25): PSI-DMP (80)-PDA (20)-FA 
After 120 minutes of reaction 
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1H NMR SPECTRA (26): f-CNTs: MWCNTs  in H2SO4 / HNO3  at 100ºC 
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1H NMR SPECTRA (27): f-CNTs: MWCNTs in H2SO4/HNO3 at 50ºC 
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1H NMR SPECTRA (28): f-CNTs: MWCNTs in H2SO4/HNO3 at RT 
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1H NMR SPECTRA (29): f-CNTs: MWCNTs + Aspartic acid
 
in DMF at 230˚C. 
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1H NMR SPECTRA (30): f-CNTs: MWCNTs + PSI in DMF
 
at 160˚C  
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1H NMR SPECTRA (31): f-CNTs (MWCNTs+H2 SO4+HNO3)-DMP (30)-FA (70) 
94% FA incorporation  
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1H NMR SPECTRA (32): f-CNTs (MWCNTs+Aspartic Acid)-DMP(40)-FA(60) 
Incorporation FA 101,3% 
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1H NMR SPECTRA (33): f-CNTs (MWCNTs+PSI)-DMP (40)-PDA (60)-FA 
Incorporation FA 105.3% 
 
 
 
 
